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Cancer is the second largest cause of death in the world. Cancer stem cells 
(CSCs) and multidrug resistant (MDR) cancer cells are two main culprits for 
cancer recurrence and metastasis. It has been reported that nanoparticles could 
bypass the P-glycoprotein (P-gp) that is overexpressed in CSCs and MDR 
cancer cells, killing these cells more effectively than free drugs. Polymeric 
micelles are extensively explored as drug carrier for the delivery of anticancer 
drugs, due to their unique core-shell structure, easy functionalization and 
passive targeting of tumor due to the enhanced permeability and retention 
(EPR) effect. Aliphatic polycarbonates have garnered much attention in the 
biomedical field due to their biodegradability, easy functionalization, and low 
toxicity in vivo. Therefore, the hypothesis of this research is that, polymeric 
micelles formed using diblock copolymers of poly(ethylene glycol) (PEG) and 
functional polycarbonates are safe and effective drug carriers for the targeted 
delivery of anticancer drugs to tumor, to specifically address the problems of 
CSCs and MDR. To prove this hypothesis, the specific aims are proposed as 
follows: 
 
(1) To evaluate the effectiveness of the combination therapy using 
DOX-loaded mixed micelles (DOX-MM) and thioridazine-loaded 
mixed micelles (THZ-MM) formed from copolymers of 
PEG/acid-functionalized polycarbonate and PEG/urea-functionalized 
xv 
 
polycarbonate in eradicating both cancer cells and CSCs, using breast 
cancer cell lines BT-474 and MCF-7 as cell models. THZ and 
THZ-MM were more effective in the inhibition of CSCs than 
non-CSCs. A stronger inhibitory effect was observed on CSCs with 
the co-delivery of DOX and THZ or DOX-MM and THZ-MM as 
compared to DOX or DOX-MM alone. In the BT-474 xenografts, the 
co-delivery of DOX-MM and THZ-MM produced the strongest 
antitumor efficacy, and both THZ and THZ-MM showed strong 
activity against CSCs. 
 
(2) To enhance the tumor targeting efficacy by preparing pH-sensitive 
micelles using the DOX and PEG/aldehyde-functionalized 
polycarbonate copolymers conjugates formed via Schiff-base bond 
and evaluate the effectiveness of these micelles on overcoming MDR 
using MDR breast cancer cell line MCF-7/Adr as cell model. 
DOX-loaded micelles showed pH-responsive drug release. The 
cellular uptake of the DOX-loaded micelles on MCF-7/Adr cells was 
much higher than free DOX. Furthermore, DOX-loaded micelles 
killed MCF-7/Adr cells more effectively than free DOX. 
 
(3) To enhance the tumor targeting efficacy by preparing pH-sensitive 
micelles using copolymers of PEG/boronic acid-functionalized 
xvi 
 
polycarbonate and PEG/urea-functionalized polycarbonate for the 
delivery of DOX. These micelles showed pH-responsive DOX release 
and higher cellular uptake than free DOX on BT-474 cells. 
DOX-loaded micelles could enhance the penetration ability of free 
DOX on BT-474 tumorspheres.  
 
(4) To optimize the micellular formulation by designing and synthesizing 
PEG replacing hydrophilic polycarbonates for the future study in the 
developing of novel micellular formulations. These polymers showed 
stealth and antifouling properties without causing toxicity in mice. 
 
The promising results showed that these micellular systems hold great 
potential for the delivery of anticancer drugs to target both cancer cells and 
CSCs, and to circumvent MDR in cancer treatment. In addition, this study also 
demonstrated that the hydrophilic polycarbonates as PEG alternatives are 
promising shell-forming materials for micelles for the future development of 
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Fig. 5.4. In vitro release of DOX from DOX/B micelles and DOX/B+U mixed 




Fig. 5.5. Confocal images of BT-474 cells after treated with free DOX, 
DOX/B micelles and DOX/B+U mixed micelles. Scale bar: 20 µm. 
 
Fig. 5.6. Cellular uptake of DOX by BT474 cells analyzed by flow cytometry. 
* p<0.05 vs. free DOX; ** p<0.01 vs. free DOX. 
 
Fig. 5.7. Viability of BT-474 cells after treated with free DOX, DOX/B 
micelles and DOX/B+U mixed micelles for 48 h. 1, p<0.01 vs. free DOX or 
DOX/B micelles; 2, p<0.01 vs. free DOX. 
 
Fig. 5.8. Viability of BT-474 cells after treated with blank micelles for 48 h. 
 
Fig. 5.9. Confocal images of BT-474 tumorspheres after treated with free 
DOX, DOX/B micelles or DOX/B+U mixed micelles for 24 h. Tumorspheres 
were scanned layer by layer using z-stack. Each layer was 10 µm. Scale bar: 
100 µm. 
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free DOX, DOX/B micelles or DOX/B+U mixed micelles for 24 h. * p<0.05 
vs. free DOX. 
 
Fig. 5.11. Morphology changes of BT-474 tumorspheres after being treated 
with medium, B blank micelles, B+U blank micelles, DOX/B micelles and 
DOX/B+U mixed micelles for 0, 3, 7, 14 and 21 days. Scale bar: 100 µm. 
 
Fig. 5.12. Live/dead assay of BT-474 tumorspheres after being treated with 
free DOX, DOX/B micelles or DOX/B+U mixed micelles for 0 day and 3 day. 
Scale bar: 100 µm. 
 
Fig. 6.1. Polymers containing hydroxyl side groups attached through an amide 
linkage. 
 
Fig. 6.2. 1H NMR in CDCl3 of poly(MTC-OC6F5) and 
1H NMR in D2O of 
polymer A-2. R = Phenyl. 
 
Fig. 6.3. Particle size measured by DLS as a function of time for 
homopolymers dissolved in 10% serum. 
 
Fig. 6.4. Cell viability of HEK293 cells after treated with water-soluble 
polycarbonates and PEG (labeled as 5 kDa and 10 kDa) for 48 h. 
 
Fig. 6.5. Particle size measured by DLS as a function of time for diblock 
copolymers substituted with serinol and 3-aminopropanol dissolved in 10% 
FBS containing PBS. 
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Fig. A4.1. 1H NMR spectrum of polymer A-3 showing integration consistent 
with quantitative substitution. 
 
Fig. A4.2. 1H NMR spectrum of polymer A-1. 
 
Fig. A4.3. 1H NMR spectrum of polymer A-2. 
 
Fig. A4.4. 1H NMR spectrum of polymer A-4. 
 
Fig. A4.5. 1H NMR spectrum of polymer A-5. 
 
Fig. A4.6. 1H NMR spectrum of polymer A-6. 
 
Fig. A4.7. 1H NMR spectrum Poly(MTC-OC6F5)50-b-Poly(MTC-OEt)20 
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Fig. A4.8. 1H NMR spectrum Poly(MTC-OC6F5)50-b-Poly(MTC-OEt)20 
substituted with 3-aminopropanol. 
 
Fig. A4.9. 1H NMR spectrum Poly(MTC-OC6F5)50-b-Poly(MTC-OEt)20 
substituted with 1-amino-2-propanol. 
 
Fig. A4.10. 1H NMR spectrum Poly(MTC-OC6F5)50-b-Poly(MTC-OEt)20 
substituted with serinol. 
 
Fig. A4.11. 1H NMR spectrum Poly(MTC-OC6F5)50-b-Poly(MTC-OEt)20 
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Cancer is a group of malignant diseases defined by uncontrolled growth and 
spread of some abnormal cells. It is the second most leading cause of death in 
the world, only after cardiovascular diseases. It was estimated by the 
International Agency for Research on Cancer (IARC) that there were 14.1 
million new cancer cases, 32.6 million people living with cancer and 8.2 
million people dead because of cancer (about 22,000 deaths per day) in 2012 
worldwide [1]. By 2030, it is estimated that the new cancer cases and the 
cancer death in the world will increase to 21.7 million and 13 million 
respectively, due to the growth and aging of the population [1]. In Singapore, 
cance is the number one cause of death, constituting 29.4 % of deaths in 2014 
[2]. The incident rate of cancer in men is almost 25 % higher than that in 
women. According to the data of World Health Organization (WHO), the three 
most common types of cancer killing men are: lung, stomach and liver cancer, 
while the three most common types of cancer killing women are: breast, lung 
and colon cancer [1]. Apart from its high morbidity and lethality-causing 
nature, cancer also incurs huge economical loss. In the US, the direct medical 
cost for cancer was about $88.7 billion in 2011 [1]. The cost is expected to 
grow due to the increasing number of new cancer cases and the ensuing 
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escalating expenses in medical care.  
 
The most commonly used methods for the treatment of cancer include surgery, 
chemotherapy and radiation therapy. Surgery can remove the tumor tissues 
from the body directly and often provides the best outcomes in some cases if 
the cancer cells have not spread to other tissues. While for metastasic cancers, 
radiation therapy and chemotherapy are more widely used. Radiation therapy 
uses high energy particles or waves to kill the cancer cells, while 
chemotherapy employs systemic injection of anticancer drugs into blood to 
destroy the cancer cells. Both radiation therapy and chemotherapy have severe 
side effects due to non-specific toxicities caused to normal cells [1,3].  
 
Despite the advances in diagnostics, prevention and treatment of cancer over 
the last few decades, multidrug resistance (MDR) is still one of the major 
problems in cancer therapy. MDR is one of the most significant reasons 
causing failure in cancer treatments and it also plays a crucial role in cancer 
recurrence and metastasis [4]. Over last few years, increasing evidences have 
been found to demonstrate the presence of cancer stem cells (CSCs) in various 
cancers [5]. This small population of cells is resistant to conventional cancer 




1.2. Multidrug resistance (MDR) in cancer 
 
MDR is defined as cancer cells that exhibit cross-resistance to a number of 
chemotherapeutic drugs that are structurally and/or functionally unrelated [6]. 
The MDR of cancer cells can be divided into two types namely intrinsic 
resistance and acquired resistance. Intrinsic resistance means that the cancer 
cells are unresponsive to the anticancer drugs at the initial treatment stage, 
while acquired resistance means that the cancer cells are responsive to the 
initial treatment, but develop resistance to the chemotherapeutics drugs when 
the treatment progresses [7]. The potential mechanisms of MDR can be 
broadly divided into cellular mechanisms and extracellular mechanisms. 
Cellular mechanisms include the overexpression of drug efflux transporters, 
increased DNA repair, apoptosis induction and altered molecular targets (Fig. 
1.1). Extracellular mechanisms include high interstitial fluid pressure (IPF), 
hypoxia induction and low extracellular pH [8]. In this section, various 
cellular mechanisms and extracellular mechanisms which are encountered 





Fig. 1.1. Cellular mechanisms responsible for the MDR. Reprinted with 
permission from references [8]. 
 
1.2.1. Adenosine triphosphate (ATP)-binding cassette (ABC) transporters 
 
Amongst the various mechanisms causing the MDR in cancer, the most 
extensively investigated is the increased drug efflux due to the overexpression 
of ABC transporter family [9,10]. In human, there are more than 48 members 
in ABC transporters family, which are divided into difference subfamilies 
based on differences in the structure [8]. Among them, 3 members are the 
most extensively studied, including P-glycoprotein (P-gp, ABCB1), multidrug 
resistant associated protein 1 (MRP1, ABCC1) as well as breast cancer 




P-gp is a 170 kDa protein encoded by ABCB1 (or MDR1) gene and contains 2 
ATP binding domains and 12 transmembrane regions. The transmembrane 
regions can bind hydrophobic drug substrates with either neutral charges or 
positive charges and then induce the ATP hydrolysis at one ATP binding site, 
subsequently leading to a conformational change of P-gp, which causes the 
efflux the drug substrates out of the cancer cells. Then the ATP hydrolysis 
happens in another ATP binding site, which will reset the P-gp for the next 
transportation. P-gp can pump out a wide range of hydrophobic anticancer 
drugs, including anthracyclines, epipodophyllotoxins, vinca alkaloids, and 
taxanes. The two most frequently used P-gp inhibitors in the laboratory and 
the clinical trial are verapamil and cyclosporin A. Besides P-gp, another ABC 
transporter, MRP1, is a 190 kDa protein encoded by ABCC1 gene and consists 
of 15 transmembrane regions attached to a P-gp like core. The substrates of 
MRP1 include anions and neutral hydrophobic drugs, as well as glutathione 
(GSH) and the conjugates of GSH. Furthermore, breast cancer resistant protein 
(BCRP), also known as MXR (mitoxantrone-resistance gene) or ABC-P (ABC 
transporter in placenta), is encoded by ABCG2 gene. This transporter contains 
two half-transporters, each of which consists of 6 transmembrane regions and 
an ATP binding domain. The substrates of BCRP include doxorubicin (DOX), 
daunorubicin, mitoxantrone and topotecan [8]. 
 
1.2.2. DNA damage and repair 
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The DNA mutation is one of the main reasons of causing cancer and many 
chemotherapeutic drugs kill the cancer cells through inducing the DNA 
damage of cancer cells directly or indirectly. The abnormal DNA repair 
capacities in cancer cells can cause MDR to the treatment. The DNA repair 
mechanisms include: (1) direct repair (DR) pathway; (2) base excision repair 
(BER); (3) mismatch repair (MMR); (4) nucleotide excision repair (NER) and 
(5) repair of double-strand break (DSB) [12]. Each of these mechanisms will 
be briefly discussed below. 
 
DR is a very unique pathway that only involves one protein, MGMT 
(O6-methylguanine-DNA methyltransferase), in the repair process. This 
protein removes one alkyl group from O6 position of a damaged guanine 
residue and transfers it to an internal cysteine residue in MGMT. Some studies 
have shown that the inactivition of MGMT gene in glioma could increase the 
sensitivities of these cells to the treatment of alkylating agents and also 
prolong the survival time of patients [13,14].  
 
Similar to DR pathway, BER pathway also repairs single-base damages, which 
are normally induced by alkylating agents, platinating agents, cytotoxic 
antibiotics and taxanes [12]. Four proteins are involved in the BER pathway, 
including apurinic-apyrimidinic endonuclease 1 (APE1), DNA polymerase 
(Pol β), flap endonuclease 1 (FEN1) and poly(ADPribose) polymerase (PARP). 
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The inhibitors of these proteins can effectively enhance the responses of 
cancer cells to chemotherapy or radiation therapy. For example, Luo et al. 
reported that treating MDA-MB-231 cells with an APE1 inhibitor, Lucanthone, 
could enhance the cell killing efficacy of the laboratory alkylating agent 
methyl methanesulfonate and the clinically relevant agent temozolomide [15]. 
Moreover, recently, one study showed that the combination therapy using 
PARP inhibitor ABT-888 with anticancer drug DOX could reverse the drug 
resistance of MDA-MB-231 cells to DOX [16]. 
 
MMR is the main pathway that plays a role in correcting the base-base 
mismatches and insertion and/or deletion loops that are formed during DNA 
replication or caused by DNA damage [17]. It has been observed that animals 
and patients with MMR-deficient malignant glioma were resistant to the 
treatment of anticancer drug temozolomide [18,19]. This drug resistance in 
animals could be reversed by using a PARP inhibitor, INO-1001 [18]. 
 
NER repairs large damages of DNA, which are usally induced by UV 
irradiation, platinum-based compounds or alkylating agents [8]. More than 30 
types of proteins are involved in NER repairs, and replication protein A (RPA) 
is one of the most important. It has been reported that a small molecular 
inhibitors of RPA, MCI13E, could sensitize the lung cancer cell line H1299 





Finally, DSB is highly devastating to cells and induced by exposure to ionic 
radiation (IR), some certain chemicals or through endogenous processes [21]. 
Two main pathways that involved in the DSB repairs are homologous 
recombination and non-homologous end joining repair [21]. The effects of 
DSB repair inhibitors in cancer treatment have been reviewed in detail in the 
literature [22]. 
 
1.2.3. Apoptosis induction 
 
Many chemotherapeutic drugs kill cancer cells through the mechanism of 
inducing apoptosis, which is characterized by cell shrinkage, blebbing of 
plasma membrane, maintenance of organelle integrity, condensation and 
fragmentation of DNA, followed by ordered removal of phagocytes [23]. 
However, it has been reported that some cancer cells develop resistance to 
apoptosis, thus inducing MDR to chemotherapeutic drugs [23]. Blc-2 is an 
anti-apoptotic protein that plays an important role in MDR caused by 
apoptosis induction mechanism. Inhibiting the activity of Bcl-2 is one way to 
reverse MDR. For example, Zou et al. reported that downregulating the 
expression of Blc-2 protein in gefitinib-resistant H1975 lung cancer cell line 
with T790M mutation by using RNA interfering (RNAi) could sensitize these 
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cells to the treatment of gefitinib, which may provide a novel strategy for the 
treatment of non-small cells lung cancer (NSCLC) [24]. 
 
1.2.4. Extracellular mechanisms 
 
Compared to normal tissues, solid tumors have abnormal vasculature 
structures, which are characterized with excessive loops, blunt-ends and 
arteriolar-venous shunts, as well as lack of lymphatic systems [25]. As a result, 
fluids and proteins can be easily released from the leaky blood vessels and 
accumulate in the interstitial environment, leading to the high interstitial fluid 
pressure (IFP) [8,25]. Many large molecular drugs such as antibodies and 
proteins enter cancer cells through convection, while the small molecular 
drugs are mainly transported into cancer cells by diffusion. Increased IFP can 
induce transcapillary fluid flow and the convective transport, which limit the 
transportation of both large molecular and small molecular anticancer drugs 
and decrease the uptakes of them into tumors, leading to drug resistance [26]. 
In addition, cancer cells also compress the blood vessels, causing decrased 
blood flow. As a result, the nutrient metabolites and break down products of 
metabolism cannot be timely removed from the tumors, leading to hypoxia 
and acidic tumor microenvironment [27].  
 
It has been reported that about 50-60 percent of local advanced tumors have 
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hypoxia, which plays an important role in causing MDR both in radiation 
therapy and chemotherapy [8]. Radiation therapy needs oxygen to generate 
reactive oxidative species (ROS) to kill the cancer cells through the damage of 
DNA. The efficacy of radiation therapy is hampered in hypoxia tumors due to 
the lack of oxygen [28]. Also, some chemotherapy drugs such as the alkylating 
agents (melphalan), the antibiotics (bleomycin) and the podophyllotoxin 
derivative (etoposide) require activation by oxidation to kill the cancer cells, 
and the effects of these drugs will be significantly decreased in hypoxia 
tumors [29]. Another characteristic distinguishing tumor and normal tissues is 
that unlike in normal tissues, cancer cells in hypoxia regions prefer to use 
glycolysis instead of oxidative metabolism to gain energy for survival and 
proliferation. The glycolysis process causes the accumulation of lactate acid, 
leading to acidification of the extracellular environment [27]. Also, cancer 
cells expel protons by proton (H+) pumps which are highly expressed on the 
cell membrane, thus maintain normal pH intracellularly but causes highly 
acidic extracellular environment. This intracellular-extracellular pH gradient 
often causes MDR to some weakly basic anticancer drugs through the “ion 
trapping” phenomenon [30]. These weakly basic anticancer drugs such as 
doxorubicin (DOX) and vinca alkaloids (vincristine) are ionized in acidic 
extracellular compartment. Compared to uncharged molecules, they are very 




1.3. Cancer stem cells (CSCs) 
 
CSCs are a group of distinct cells that are present in tumor cells with the 
characteristics of self-renewal, multi-differentiated potential, and high 
tumorigenicity. These cells are believed to be responsible for the failure in 
cancer treatment due to their resistance to conventional treatments and their 
abilities of differentiation [31,32]. Conventional treatments can kill the bulk of 
cancer cells but cannot eradicate CSCs. These survived CSCs could actively 
proliferate, differentiate, and form new tumor, cause cancer relapse as well as 
metastasis. Thus, developing a new therapy strategy that can target both cancer 
cells and CSCs is a promising way for cancer therapy, especially for the 
treatment of clinically metastasic cancers. 
 
The presence of CSCs was initially demonstrated by Bonnet and Dick in acute 
myeloid leukaemia (AML) in 1997 [33]. Following that, the existence of 
CSCs have been confirmed in a range of cancers, including B and T acute 
lymphoblastic leukaemia [34-36] and a variety of solid tumors such as breast 
[37], pancreas [38, 39], colon [40, 41], lung [42] and glioblastoma [43]. 
 
In this section, various methods that are used to sort out and identify CSCs and 
mechanisms of causing drug resistance in CSCs will be briefly reviewed. 




1.3.1. Characteristics of CSCs 
 
CSCs are a small population of cells within cancer cells, thus various assays 
have been developed to identify and separate these cells. One of the most 
widely used methods for CSCs sorting is side population sorting technology 
by using fluorescence-activated cell sorting (FACS). In this assay, the cancer 
cells were stained by Hoechst 33342, a kind of DNA supplemental dye that 
binds to the AT rich canaliculus of DNA. A small population of cells cannot be 
stained by this dye, and these cells are dark when detected by FACS. This 
group of cells was called side population cells, and this separation method is 
called side population sorting technology. The principle is that the ABC 
transporters overexpressed in the membrane of CSCs can pump out of Hoechst 
33342 and these cells appear weakly stained [44,45]. Many studies have 
successfully sorted out CSCs in various cancer cell lines by side population 
sorting [46-48].  
 
Another method used to sort CSCs is based on the biomarkers in the surface of 
CSCs. For example, Al-Hajj and colleagues found that human breast CSCs are 
enriched in a subpopulation CD44+/CD24-/Lin- subpopulation of breast 
cancer cells [37]. These cell surface markers have been used for the isolating 
and identification of breast CSCs. However, the isolated CSCs by using this 
method have poor homogeneity, and can be further divided into different 
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subgroups, some of which can not form tumor in mice, suggesting that they 
are not complete breast CSCs [49]. Apart from the biomarkers mentioned 
above, some other biomarkers also have been reported for the sorting of CSCs, 
including ITGA 6/α6-integrin [50], CD133/PROM1/prominin [51-53], 
CD29/β1-integrin and CD61/β2-integrin [54,55]. 
 
Moreover, the enhanced aldehyde dehydrogenase (ALDH) activity is a 
hallmark of CSCs [56]. The ALDH enzymes are a family of evolutionarily 
conserved enzymes that include 19 isoforms, one of which is generally 
believed to be responsible for the ALDH activity of CSCs [57]. The ALDH 
can transform one of its substrates BAAA (Bodipyaminoacetaldehyde) to the 
fluorescent product BAA (Bodipyaminoacetate). Cells with high ALDH 
expression have bright fluorescence, which can be detected and the cells can 
be sorted out by FACS. By using this method, Cheung et al. firstly isolated the 
leukemia stem cells in 2007 [56]. The same year, Ginestier et al. successfully 
isolated CSCs from breast tumor tissue. In this study, they found that as few as 
500 ALDH1+ cells could form tumors in nonobese diabetic/severe combined 
immunodeficiency (NOD/SCID) mice. In contrast, 50,000 ALDH1- cells 
failed to cause tumor formation [49]. 
 
Despite the availability of the above-mentioned CSC sorting strategies, cells 
isolated and sorted through various methods need to be further analyzed to 
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confirm their identity. The classic method for identifying CSCs is using in vivo 
animal models. The specific subpopulation of cells is injected into mice and 
then the tumorigenicity is compared with that of non-CSCs at different 
dilutions [37]. Additionally, the mammosphere forming assay has also been 
served as an in vitro method for documenting CSCs. The principle is that 
CSCs can form mammospheres in non-serum medium, while non-CSCs 
cannot [58]. 
 
1.3.2. CSCs are resistant to conventional cancer treatments 
 
Some studies have demonstrated that CSCs are resistant to both chemotherapy 
and radiation therapy. Tanei et al. reported that after treating with paclitaxel 
(PTX) and epirubicin-based chemotherapy, the percentage of ALDH+ cells 
were enriched in breast tumors [59]. Similarly, Yu et al. showed that 
neoadjuvant chemotherapy to breast cancer patients could enhance the fraction 
of CSCs (CD44+/CD24−/low tumor cells) and augments mammosphere 
formation in vitro [60]. The resistance to chemotherapy of CSCs has also been 
demonstrated in mouse model. Yu et al. injected consecutive passage of 
human breast cancer cells into mice and established the tumor model. 
Administration of an anticancer drug epirubicin to the tumor bearing mice 
could significantly increase the fraction of CD44+/CD24−/low cells [60]. 
Some studies also showed that radiation therapy could enhance the percentage 
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of CSCs in xenografts [61,62]. 
 
Some mechanisms that cause drug resistance in CSCs have been described. 
One of the main reasons is the high expression levels of specific ABC 
transporters on CSCs, such as P-gp (ABCB1), MRP1 (ABCC1) as well as 
BCRP (ABCG2) [32]. These transporters can pump out the free drugs from the 
cancer cells, leading to durg resistance. Signaling pathways such as Notch and 
Wnt are also associated with the resistance of chemotherapy [63] and radiation 
therapy [62,64] of CSCs. Moreover, some studies demonstrated that an 
epithelial-mesenchymal transition (EMT)-like process associates with MDR of 
CSCs. Li et al. found that breast cancer cells that underwent EMT were 
resistant to two common anticancer drugs vincristine and PTX in vitro [65]. 
This effect was also demonstrated in other kinds of tumors. Tumors collected 
from patients with residual cancers [66] or pleural effusions [60] after 
treatment expressed high levels of mesenchymal EMT markers. Because of 
their tumorigenic properties and resistance to therapy, CSCs have been 
thought to be implicated in the cancer relapse and metastasis in clinic [67]. 
 
1.3.3. Agents for targeting CSCs 
 
Despite  the nature of resistance of CSCs to the conventional radiation 
therapy and chemotherapy, several small molecular agents have been found to 
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effectively target CSCs, for example, biguanides (metformin and phenformin) 
[68,69], salinomycin [70], curcumin [71], thioridazine [72], piperine [73], 
curcumin [73], tariquidar [74], lapatinib [75], epigallocatechin-3-gallate 
(EGCG) [76] and parthenolide [77] etc.. However, wide applications of these 
drugs on clinical use are restricted by the limitations of poor water solubility, 
short blood circulation time and non-specific toxicities to normal tissues. For 
example, salinomycin is a polyether antibiotic isolated from Streptomyces 
albus. One study showed that salinomycin can specifically decrease the 
fraction of CD44+/CD24-/low CSCs in breast cancer [70]. It has also been 
shown that salinomycin is able to selectively target human breast CSCs in 
tumorspheres and inhibit breast cancer growth as well as metastasis in mice 
[70]. However, in this study, salinomycin was administrated to mice by 
intraperitoneal injection with the aid of ethanol, due to its hydrophobicity [70]. 
Another drug, phenformin, an anti-diabetic drug, has been found effective in 
targeting CSCs [69]. However, this drug has been withdrawn by FDA due to 
its fatal systemic toxicities [78]. Therefore, there is an urgent need to develop 
novel drug carrier systems for the delivery of these agents to target CSCs both 
safely and effectively. 
 
1.4. Polymeric micelles 
 
Amphiphilic copolymers can spontaneously self-assemble into core/shell 
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nanostructured micelles in aqueous solution at concentrations above the 
critical micelle concentration (CMC). Polymeric micelles are promising 
carriers for the delivery of anticancer therapeutics, and several types of 
polymeric micelles have already seen application in hospital settings or being 
investigated in clinical trials [79-83]. Compared with other drug delivery 
systems, polymeric micelles have a number of important properties. These 
include a unique core/shell structure composed of a hydrophilic exterior and a 
hydrophobic interior, nanosize, and easy modification of core functionalities 
and surface chemistry. In this section, micelles self-assembled via 
non-covalent (e.g. hydrophobic, hydrogen bonding, and ionic) and covalent 




Fig. 1.2. Schematic presentation of micellar drug delivery systems 
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self-assembled through (A) hydrophobic interaction; (B) hydrogen bonding 
interaction; (C) ionic interaction; (D) chemical cross-linking and (E) chemical 
conjugation. Reprinted with permission from references [83]. 
 
1.4.1. Hydrophobic interaction 
 
Hydrophobic interactions are the most extensively studied non-covalent 
interactions and the driving force for the spontaneous self-assembly of 
amphiphilic diblock copolymers into micelles in water. Hydrophobic 
interactions are widely employed in the design of most micellar drug delivery 
systems. Amphiphilic copolymers with various architectures, including block, 
graft, star and hyperbranched copolymers, have been investigated for micellar 
drug delivery, and structure-function relationships have been established as a 
function of architecture. Among these copolymers, the block copolymers are 
the most commonly reported materials used to prepare micelles for drug 
delivery. Genexol®-PM is the first commercially available polymeric micelle 
formulation for the treatment of NSCLC, ovarian cancer, breast cancer and 
gastric cancer [79]. In this formulation, the hydrophobic anticancer drug PTX 
was loaded into monomethoxy poly(ethylene glycol)-block-poly(D,L-lactide) 
(mPEG-PDLLA) micelles through hydrophobic interactions [84,85]. Kataoka 
et al. also developed PTX-loaded polymeric micelles (denoted as NK105) for 
PTX delivery [86]. In this case, poly(ethylene glycol)-poly(aspartic acid) 
(PEG-P(Asp)) block copolymer was conjugated with 4-phenyl-1-butanol 
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through acid groups in the P(Asp) block to increase hydrophobicity for 
improved PTX loading. On colon 26-bearing CDF1 mice, the plasma and 
tumor area under the curve values of NK105 were about 90-fold and 25-fold 
higher than that of free PTX. On a human colorectal cancer cell line HT-29 
xenograft, the antitumor activity of NK105 at a dose of 25 mg/kg was 
comparable to that of free PTX at a dose of 100 mg/kg. After treatment with 
NK105 at a dose of 100 mg/kg, tumors in all mice disappeared. Compared 
with free PTX, NK105 showed milder neurotoxicity, which was demonstrated 
by both histopathological (p<0.001) and physiological (p<0.05) methods [86]. 
A phase II clinical trial of NK105 against advanced or recurrent gastric cancer 
was successfully conducted, and the results were promising [87]. 
 
Compared with linear diblock copolymers, graft copolymers were reported to 
have lower CMC and greater drug loading capacity. For example, Jiang et al. 
compared a diblock copolymer of methoxy poly(ethylene 
glycol)-b-poly(5-allyloxy-1,3-dioxan-2-one) (mPEG-b-PATMC) with a graft 
copolymer, which was formed by grafting PATMC onto mPEG-b-PATMC 
(mPEG-b-(PATMC-g-PATMC)) [88]. The graft copolymer formed micelles at 
a much lower concentration and the particle size of graft copolymer micelles 
was smaller than that of micelles formed from the diblock copolymer 
mPEG-b-PATMC. The graft copolymer micelles also had greater drug loading 
capacity and drug loading efficiency compared with diblock copolymer 
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micelles. In another study, reducible amphiphilic polyamide 
amine-g-poly(ethylene glycol) (PAA-g-PEG) graft copolymers containing 
disulfide linkages were synthesized and utilized to load DOX into micelles. 
The micelles prepared from the polymer with the optimal compositions 
yielded high drug loading capacity (25 wt.%) and nanosize (44 nm), 
suppressed tumor growth more effectively than free DOX in a 4T1 mouse 
breast cancer model [89]. 
 
In addition to graft polymers, hyperbranched and star copolymers have also 
been extensively explored for micelle preparation to enhance drug loading 
capacity since the multiple hydrophobic chains may increase interactions with 
hydrophobic drugs. For instance, micelles prepared from hyperbranched 
polypeptide and poly(ethylene glycol) (PEG) block copolymers were used to 
encapsulate DOX [90]. The hyperbranched block copolymers were 
synthesized in two steps. Hyperbranched poly(ε-benzyloxycarbonyl-L-lysine) 
(HPlys) with multiple alkyne groups was synthesized via click chemistry by 
using Plys with α-thiol and ω-alkyne terminal groups, which was further 
conjugated with thiol-functionalized PEG to afford HPlys-b-PEG block 
copolymers. HPlys-b-PEG had a 5-fold lower CMC, higher DOX loading 
level/efficiency, greater yield and a more sustained drug release profile than its 




1.4.2. Hydrogen bonding interaction 
 
Hydrogen bonding interactions are another widely used strategy for the 
self-assembling of micelles to enhance the micelles stability and drug loading 
levels. Yang and coworkers demonstrated that the incorporation of hydrogen 
bonding urea functionalities in the hydrophobic block of amphiphilic diblock 
copolymers significantly lowered CMC of block copolymers, stabilized the 
micelles and improved drug loading and facilitated the formation of stable 
drug-loaded micelles, yet did not induce significant cytotoxicity. The polymers 
were synthesized through ROP of urea-functionalized cyclic carbonates using 
mPEG as a macroinitiator. Ureas are known to associate via bifurcated 
hydrogen bonds. Ureas are also known to bind carboxylate derivatives and 
their isosteres (such as sulfonates, phosphonates, and phosphates), which 
provides a possible mode of interaction with drug molecules. These findings 
highlight the importance of the control of non-covalent interactions for 
supramolecular drug-delivery [91,92]. Since carboxylates and ureas form 
bifurcated hydrogen bonds, urea- and carboxylic acid-functionalized 
poly(carbonate) and PEG diblock copolymers (PEG–PUC and PEG–PAC) 
with narrow molecular weight distributions (polydispersity indices: 1.14–1.20) 
were synthesized and employed to prepare mixed micelles via 
hydrogen-bonding interactions between urea and acid groups [93] (Fig. 1.3A). 
Although PEG–PAC diblock copolymer had high loading capacity for 
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amine-containing DOX (39 wt.%) due to the strong ionic interaction between 
the acid group in the polymer and the amine group in the drug, the 
DOX-loaded micelles formed large aggregates having particle size of 595 nm. 
In addition, they were not stable in the presence of a destabilizing agent (i.e. 
SDS) and most micelles were dissociated in 30 min. In sharp contrast, the 
mixed micelles formed from PEG–PUC and PEG–PAC were able to load 
DOX into nano-sized micelles with narrowsize distribution at high drug 
content (166 nm; polydispersity index: 0.18; DOX loading level: 32 wt.%). 
Importantly, the presence of the urea-functionalized polycarbonate 
tremendously enhanced the stability of DOX-loaded micelles, and the micelles 
remained stable even in the presence of SDS and serum proteins over 48 h. 
The results of in vitro release studies showed that DOX release was sustained 
over 8 h without obvious initial burst release (Fig. 1.3B) [94]. The DOX 
loaded mixed micelles effectively suppressed the proliferation of HepG2 and 
4T1 cancer cell lines. The in vivo biodistribution studies conducted in a 4T1 
mouse breast cancer model with a single i.v. injection of 8 mg/kg DiR-loaded 
mixed micelles demonstrated that the mixed micelles were preferably 
transported to the tumor even at 5 days post administration [95]. The 
concentration of the micelles in the blood after injection was estimated to be 
about 100 mg/L provided the volume of mouse blood is 1.6mL,which was 
much higher than the CMC value of the micelles (16.8 mg/L), suggesting that 
the micelles would be stable during the blood circulation. This was in good 
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agreement with the findings obtained from the in vivo biodistribution study. In 
the same tumor model, DOX-loaded micelles inhibited tumor growth more 
effectively than free DOX (percentage of tumor volume: 500 % vs. 1350 % at 
26 days post treatment, Fig. 1.3C) without causing body weight loss (0–15 % 
increase at 26 days post treatment, Fig. 1.3D) or cardiotoxicity (apoptotic cells 




Fig. 1.3. Polymeric micelles stablized by H-bonds formed between acid and 
urea groups, which are installed in the hydrophobic blocks 
poly(carbonate-urea) (PUC) and poly(carbonate-acid) (PAC) of diblock 
copolymers of PEG-PUC and PEG-PAC, for the delivery of DOX. (A) 
Synthesis of PEG-PUC and PEG-PAC, and preparation of DOX-loaded mixed 
micelles (DOX-MM) formed from PEG-PUC and PEG-PAC. (B) In vitro 
release profiles of DOX-loaded mixed micelles in PBS (pH 7.4) at 37 ° C; (C) 
tumor volume and (D) body weight changes over 26 days for mice bearing 
4T1 tumors administered with PBS (control), free DOX, DOX-loaded 5 kDa 
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PEG and 10 kDa PEG mixed micelles and their respective blank micelles. 
Percentage of tumor volume or body weight was calculated by dividing the 
tumor volume or weight at a given time point over the respective values at day 
0 and being multiplied by 100 %. 5 mg/kg of DOX for free DOX and 
DOX-loaded mixed micelles and the equivalent weight of blank mixed 
micelles were given at days 0, 4, 8 and 12. The symbols * and + indicate 
significant difference in (C) tumor volume or (D) body weight between 
DOX-loaded 5 kDa PEG mixed micelle-treated and free DOX-treated mice 
and between DOX-loaded 5k PEG mixed micelle-treated and 10 kDa PEG 
mixed micelle treated mice respectively (p<0.05). Histological analysis of 
hearts at the end of anti-tumor study for TUNEL-positive apoptotic bodies 
from a representative mouse in each treatment group. Heart sections from a 
mouse injected with PBS (E); treated with four doses of 5 mg/kg free DOX (F) 
and four doses of 5 mg/kg DOX-loaded 5 kDa PEG mixed micelles (G).Many 
apoptotic bodies are seen in the mouse treated with free DOX, while there are 
few apoptotic bodies observed in the mouse treated with the DOX-loaded 
micelles. Reprinted with permission from reference [83]. 
 
1.4.3. Ionic interaction 
 
Ionic interactions are long-range interactions that involve the electrostatic 
attraction between oppositely-charged ions, i.e. cations (positive) and anions 
(negative). Ionic interactions have been widely employed as a tool to form 
micelles for drug delivery. Compared with micelles that are self-assembled 
through hydrophobic and hydrogen bonded interactions, micelles formed by 
ionic interactions have the added advantage of encapsulating ionic compounds 
such as small molecule drugs, therapeutic proteins, peptides and nucleic acids.  
 
Ionic interactions have been widely used as a tool for preparing stable 
polyionic complex (PIC) micelles for encapsulating charged small molecule 
25 
 
drugs. For instance, all-trans retinoic acid in its deprotonated form is an 
anionic drug that can be loaded into the cationic copolymer poly(ethylene 
glycol)-graft-chitosan to form PIC micelles that are stabilized by ionic 
interactions [96]. The drug loading efficiency was higher than 80% and the 
drug-loaded micelles showed more sustained drug release in vitro than the free 
drug. Yang et al. prepared PIC micelles based on methoxy poly(ethylene 
glycol)-graft-chitosan (mPEG-g-Chitosan) and lactose-conjugated 
PEG-graft-chitosan (Lac-PEG-g-Chitosan) for the delivery of the anionic drug 
diammonium glycyrrhizinate (DG) [97]. The drug loading efficiency of 
DG-loaded regular PIC micelles and lactose modified PIC micelles were 
97.4% and 96.7%, respectively. The two micelles were stable in acetate buffer 
(pH 3.5, 1%) for 3 months without aggregation. Just as anionic drugs can be 
loaded into polycations, cationic drugs can also be loaded into anionic 
copolymers to form PIC micelles. For example, a cationic drug imipramine 
hydrochloride was loaded into a four-arm poly(ethylene 
oxide)-b-poly(methacrylic acid) block copolymer through the ionic interaction 
between the negatively-charged carboxylate groups on the polymer chains and 
the positively-charged imipramine hydrochloride [98]. 
 
Proteins and peptides contain many charged moieties and may show an overall 
negative or positive charge in different pH depending on their characteristic pI 
(isoelectric point) values. Their charged nature makes them suitable for 
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encapsulation into micelles via ionic interactions. For example, our lab 
reported on the loading of the anticancer protein lectin A-chain into cationic 
micelles based on biodegradable and amphiphilic copolymers [99]. The lectin 
A-chain loaded cationic micelles showed much smaller particle sizes and 
stronger positive charges than the commercial product BioPorter and lectin 
A-chain complexes (150 nm vs. 455 nm; +30mV vs. +20mV). Consequently, 
the cationic micelles exhibited much higher delivery efficiency than BioPorter 
in various cancer cell lines. Besides cationic micelles, PIC micelles 
self-assembled through the ionic interaction between proteins/peptides with 
the charged segment of PEG-based copolymers, can also be formed to 
improve drug loading capacity and kinetic stability. Kataoka and coworkers 
reported core-shell-type PIC micelles formed by lysozyme and PEG–P(Asp) 
[100]. These micelles had an extremely narrow size distribution with an 
average diameter of 47 nm. 
 
By virtue of the overall negative charge on nucleic acids, ionic interactions 
represent the key driving force in facilitating their incorporation into micelles 
with improved stability in vitro and in vivo [101]. Yang and coworkers had 
previously designed and synthesized a cationic amphiphilic copolymer 
P(MDS-co-CES) containing tertiary amine groups for intracellular gene 
delivery via the “proton-sponge” effect [102]. The copolymer self-assembled 
into cationic micelles with a CMC value of 10 mg/L. These micelles 
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effectively delivered DNA and siRNA into various human cancer cell lines, 
and showed lower toxicity and higher transfection efficiency than 
polyethylenimine (PEI, 25 kDa) [103,104]. In addition, they also reported 
cationic micelles self-assembled from amphiphilic oligopeptides and used 
them for gene delivery [105,106]. The use of these micelles resulted in higher 
gene expression efficiency compared to peptide carriers that did not form 
micelles. 
 
1.4.4. Chemical cross-linking  
 
Conventional micelles exist in solution only at concentrations higher than their 
CMC, below which they become thermodynamically unstable and 
spontaneously disintegrate, leading to premature drug release. This represents 
a major obstacle for intravenous delivery applications, as the micelle 
experiences infinite dilution as soon as it is injected into the bloodstream. To 
overcome this limitation, cross-linking strategies have been explored to 
enhance micelle stability. Various strategies have been developed for the 
preparation of cross-linked micelles and a range of stimuli-sensitive linkages 
have been introduced into these systems to achieve on-demand drug release to 
targeted sites [107,108]. Based on the location of the cross-linking, 
cross-linked micelles can be categorized into core cross-linked, shell 




Cross-linking of the micelle core has been proven to enhance micelle stability 
and prevent destabilization upon dilution. For example, Shuai et al. reported 
core cross-linked (CCL) polymeric micelles for PTX delivery [109]. The 
multistep polymer syntheses involved ROP of ε-caprolactone (CL) initiated by 
mPEG in the presence of tin (II) octanoate followed by end-capping with a 
reactive maleic moiety; subsequent esterification of the acid-terminated 
intermediate with mPEG-PCL gave the desired triblock copolymer, 
mPEG-PCL-mPEG, in greater than 95% yield. The micelles were then 
cross-linked by radical polymerization via the double bond of the maleic 
group. Compared with non-cross-linked micelles, the CCL micelles exhibited 
a significantly enhanced thermodynamic stability and PTX-loading efficacy. 
 
Shell cross-linked (SCL) micelles consist of amphiphilic copolymers that 
self-assemble to form a hydrophobic core and hydrophilic shell, the latter of 
which is chemically cross-linked, usually in a step following micelle formation. 
The crosslinking of the micellar shell can enhance the stability of micelles 
under environmental variations, such as ionic strength, solvent system, and pH, 
and can also affect the drug loading capacity and drug release profile. Kim et 
al. reported preparation of SCL micelles as carriers for albendazole by using 
poly(ethylene glycol methyl ether methacrylate-co-methacrylic 
acid)-block-poly(methyl methacrylate) block copolymer [110]. Shell 
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cross-linking using 1,8-diaminooctane significantly increased the micelle 
stability in cell culture media and had a major effect on the rate of drug release, 
dramatically reducing the amount of drug released from 50% 
(non-cross-linked) to around 20% (cross-linked) over a 30 h incubation period. 
 
While core and shell cross-linking have been shown to impart improved 
stability upon micelles when compared against their non-cross-linked 
counterparts, several disadvantages exist for these systems. For instance, 
synthesis of shell cross-linked micelles often results in unintended inter 
micellar cross-linking, an unwanted side-reaction that requires tedious 
optimization in order to avoid [107]. Furthermore, shell cross-linking also 
reduces the fluidity and hydrophilicity of the micelle. Core cross-linking, on 
the other hand, can limit the mobility of the micellar core as well as its drug 
loading capacity. Intermediate layer cross-linked micelles have been 
hypothesized to alleviate these issues [111]. Recently, Desale et al. synthesized 
triblock copolymers containing blocks of poly(ethylene glycol), polyglutamic 
acid and polyphenylalanine (PEG–PGlu–PPhe) to form intermediate layer 
cross-linked micelles comprised of a PPhe hydrophobic core, a cross-linked 
ionic PGlu intermediate shell layer, and a PEG corona [112]. These micelles 
incorporated a combination of two drugs, cisplatin and PTX (cisplatin loading 
level: 15 wt.%; PTX loading level: 9 wt.%), and the resultant dual drug loaded 
micelles demonstrated synergistic cytotoxicity against human ovarian A2780 
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cancer cells, exemplified by enhanced antitumor activity compared with 
cisplatin-loaded micelles, PTX-loaded micelles or free cisplatin in an ovarian 
A2780 cancer xenograft mouse model (survival time: 45 days vs. 22 days, 16 
days and 20 days respectively). 
 
1.4.5. Chemical conjugation 
 
Micelles assembled by polymer-drug conjugates have been extensively 
explored as emerging drug delivery systems over the past decades [80, 113]. 
Their micellar self-assembly in aqueous solution helps improve solubility, 
increase payload and enhance stability of the therapeutics. To avoid premature 
cargo release in the blood stream and achieve rapid drug release in target sites, 
the drugs are linked to the polymeric backbone through bonds that are 
responsive to environmental or physiological stimuli, such as the lower pH in 
tumor tissue, reducing environment in cells or temperature change, to achieve 
a modulated drug release. Furthermore, various targeting ligands can be 
decorated on the micellar surfaces to attain active targeting [80]. The major 
polymeric platform for the preparation of polymer-drug conjugation micelles 
include polyethylene glycol (PEG), poly(N-(2-hydroxypropyl)methacrylamide 
(PHPMA) and poly(glutamic acid) (PGA).  
 
PEG is a linear non-biodegradable polyether that is industrially manufactured 
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from ethylene oxide in the presence of an acidic or basic catalyst. It is a 
FDA-approved, hydrophilic polymer that is biocompatible and non-toxic to 
the human body. Several anticancer PEG–drug conjugates are currently in 
clinical trials [114,115], including PEG-SN38 (SN38 = 
7-ethyl-10-hydroxy-camptothecin; EZN-2208) [116,117], PEG-CPT-11 
(CPT-11 = irinotecan (semisynthetic analog of camptothecin); NKTR-102) 
[115] and PEG-DTX (DTX = docetaxel; NKTR-105) [115]. PHPMA is 
another hydrophilic polymer that can be used in lieu of PEG. Importantly, it is 
non-immunogenic and non-toxic although it is also considered 
non-biodegradable. PHPMA–DOX was the first polymer-drug conjugate 
system to enter clinical trial in 1994 [118], and there has been significant 
progress made towards clinical applications since then. Besides CPT and PTX 
[119], PHPMA has also been employed in the chemical conjugation to DOX 
(PHPMA-DOX (PK1/FCE-28068) [118,120,121], PHPMA-DOX-Gal (Gal = 
galactose; PK2/FCE-28069) [120,122]) and platinum-based drugs 
(PHPMADACH-platinate (DACH = diaminocyclohexane; 
AP5346/ProLindac™) [123–125] as well as PHPMA-malonato-platinate 
(AP5280) [126,127]). Unlike PEG and PHPMA, PGA is a poly amino acid 
that is biodegradable. It is generally non-toxic and well-tolerated in the body. 
There are currently two PGA–drug conjugates in clinical trials, namely 




1.5. Stimuli responsive polymeric micelles 
 
As described in the last section, polymeric micelles have been widely explored 
as drug carriers for the delivery of anticancer drugs. However, most micellar 
systems reported so far have a premature drug release before they reach the 
tumor site, and are unable to provide timely intracellular drug release after 
they enter into tumor cells via endocytosis, which have a negative impact on 
fulling realizing the pharmaceutical potential of the enclosed anticancer drugs 
[82,133]. One promising method to tackle these problems is developing 
stimuli responsive micellular systems, which are stable in blood circulation 
and only release the payload in tumors or cancer cells due to the abnormal 
conditions in tumor tissues and intracellular microenvironments [133] (Fig. 
1.4). Various stimuli responsive micellular systems have been reported, such 
as pH-sensitive, redox-sensitive, temperature-sensitive and light-sensitive 
systems etc. [133]. Among them, pH-sensitive and redox-sensitive micelles are 
the most widely reported ones. In this section, these two types of stimuli 






Fig. 1.4. Schematic illustration of polymeric micelles which can respond to a 
range of stimuli characteristic of tumor tissues and intracellular 
microenvironments, promoting targeted delivery and controlled release of 
therapeutic drugs in tumors and cancer cells. Reprinted with permission from 
reference [133]. 
 
1.5.1. pH-sensitive micelles 
 
As discussed in section 1.2, the extracellular environments in tumor tissues 
have lower pH compared with normal tissues and blood stream (6.5-6.8 vs. 
7.2-7.4). In addition, the lysosomal and endosomal environments in cancer 
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cells are highly acidic (pH 5.0-6.5) [30]. Various pH-responsive micellular 
systems have been designed for the intratumor or intracellular drug delivery. 
These systems are stable in blood circulation but could effectively and timely 
release the loaded drugs in the acidic environments of tumors and inside 
cancer cells, thus reduce the non-specific toxicity to normal tissues and 
achieve targeted and enhanced anticancer activity. To achieve pH responsivity, 
pH-sensitive functional groups can be introduced to the micelle-forming block 
polymers, and another strategy is by introducing acid-cleavable linkage in 
polymers or between polymers and drugs to form drug-polymer conjugate 
micelles. 
 
Poly(L-histidine) (PHis) with imidazole pendant groups is extensively 
investigated to prepare pH-sensitive polymeric micelles. The imidazole groups 
are neutral at normal physiological pH and become positively charged at low 
pH due to protonation [133]. Bae’s group reported a pH-sensitive micellular 
system using pHis-PEG diblock copolymer. The micelles were prepared by 
dissolving polymer in dimethyl sulfoxide (DMSO) and then dialyzing against 
a borate buffer at pH 8. The CMC value of this polymer significantly 
increased when the pH of the medium changed from 8 to below 7.2, which 
indicated that these micelles were more stable at pH 8 than that at pH below 
7.2. However, these micelles were unstable under pH 7.4, due to the 
protonation of imidazole groups [134]. To further optimize the pH sensitive 
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range, the same group synthesized tri-block copolymer poly(L-lactic acid) 
(PLA)-PEG-pHis, as a pH-sensitive anticancer drug carrier [135]. Micelles 
were prepared using the same method as mentioned above, and reported to 
have flower structure with PLA and pHis in the core and PEG in the shell. At 
slightly acidic condition, the micelles core would be deformed due to the 
ionization of the imidazole groups, leading to pH-responsive drug release. The 
pH-insensitive hydrophobic block PLA was used to stabilize the core of 
micelles.  
 
Another pH responsive drug delivery system was developed by Eckman et al., 
which are PIC micelles formed by block copolymer PEG-poly(aspartate) 
(PEG–p(Asp)) with the cationic drug DOX hydrochloride loaded [136]. 
Carboxyl groups of p(Asp) were present as benzyl ester (PEG–p(Asp/Bz)), 
sodium salt (PEG–p(Asp/Na)) or free acid (PEG–p(Asp/H)). The drug loading 
of PEG–p(Asp/Na) and PEG–p(Asp/H) micelles were much higher than that 
of PEG–p(Asp/Bz) micelles (56.8 wt.% and 40.6 wt.% vs. 1.1 wt.%) due to the 
strong ionic interactions within the PEG–p(Asp/Na) and PEG–p(Asp/H) 
micelles. The release kinetics of DOX from PEG–p(Asp/Bz) micelles were 
unaffected by pH (i.e. identical at pH 7.4 and 5.0) as the PEG–p(Asp/Bz) 
micelles are assembled and stabilized through hydrophobic rather than ionic 
interactions [136]. In contrast, for micelles such as (PEG–p(Asp/Na)) and 
(PEG–p(Asp/H)) that are assembled by ionic interactions, the release of DOX 
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was much faster at pH 5.0 than at 7.4 (90% vs. 70–75% released over 48 h), 
whereby the lower pH neutralizes the negative charges of the copolymer, 
weakens the ionic interactions, and consequently destabilizes the micelles. 
 
Acid labile polymers also have been used for the preparation of pH-sensitive 
micelles. These polymers are generally stable at pH 7.4, but are hydrolyzed at 
mildly acidic conditions, leading to the rapid drug release. For example, Heller 
et al. reported pH-sensitive polymeric micelles comprising of PEG-poly(ortho 
ester) (POE) block polymers. Due to the highly hydrophobic property of POE, 
these micelles are suitable for the encapsulation of hydrophobic drugs such as 
DOX and PTX. Additionally, POE block is pH sensitive and degrade rapidly 
under acidic conditions, leading to the release of payload [137]. In another 
case, Kataoka et al. reported a novel protein delivery system for intracellular 
delivery based on charge-conversional PIC micelles. A copolymer 
PEG-poly(N-(N’-(2-aminoethyl)-2-aminoethyl)aspartamide) (PEG–pAsp(ED
A)) bearing primary amines on the side chains was modified with citraconic 
anhydride (Cit) to afford the negatively-charged copolymer 
PEG–pAsp(EDA-Cit) with pendant carboxylate groups. This polymer formed 
PIC micelles when combined with lysozyme, a positively-charged protein, at 
neutral pH. Upon endocytosis and subsequent uptake into the endosome, the 
acid-promoted degradation of the citraconic anhydride resulted in a change in 
overall charge of the copolymer from negative to positive, which consequently 
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led to the dissociation of the PIC micelles and protein release [138]. 
 
Apart from introducing acid labile linkage into the micelles-forming polymer, 
another strategy is conjugating polymer and drug through acid-cleavable 
linkages such as hydrazone or Schiff-base bond to form pH-sensitive 
drug-polymer conjugate micelles. For example, Kataoka and his coworkers 
reported pH-sensitive micelles based on the conjugate between DOX and 
PEG-poly(aspartate) via hydrazone bond. These micelles were stable at 
physiological pH and rapidly release DOX at lysosomal or endosomal pH due 
to the hydrolysis of hydrazone bond. Furthermore, these micelles showed 
strong antitumor activity and low toxicity in SPF CDF1 mice bearing C26 
tumor [139]. Also, Prabaharan et al. synthesized amphiphilic hyperbranched 
block copolymer, Boltorn® H40-poly(L-aspartat)-b-PEG/FA-conjugated PEG 
(H40-P(LA-DOX)-b-PEG-OH/FA) as drug carrier for DOX. DOX was 
conjugated to the hydrophobic block of these polymers via pH-sensitive 
hydrazone bond. The release of DOX at pH 5 was much faster than that at pH 
7.4, due to acid-cleavable hydrazone bond [140]. 
 
1.5.2. Redox-sensitive micelles 
 
Compared with extracellular environment, the intracellular cancer cell 
environments have much higher concentration of GSH (~ 10mM) [133]. This 
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drastic concentration gradient of glutathione between the intra- vs. 
extra-cellular environment has also been widely exploited for the design of 
redox-responsive micelles. A popular approach for fabricating such 
redox-responsive micelles involves the use of disulfide linkages as micellar 
core (or shell) cross-linking agents, which can subsequently be cleaved in a 
reductive environment such as the interior of a cell, thereby releasing the 
payload. In one example, Zhong et al. reported reversible redox-responsive 
core cross-linked micelles based on poly(ethylene 
glycol)-b-poly(N-2-hydroxypropyl methacrylamide)-lipoic acid conjugates 
and investigated their use for triggered DOX release [141]. The in vitro release 
results showed that only about 23.0 % of DOX was released in 12 h from 
cross-linked micelles at 37 °C, whereas about 87.0 % of DOX was released in 
the presence of 10 mM dithiothreitol (DTT) under otherwise similar 
conditions. Li et al. reported PTX-loaded reversible disulfide core cross-linked 
micelles (PTX-DCMs) formed from the self-assembly of thiolated 
telodendrimers and cross-linked by the oxidization of thiol groups to disulfide 
bonds [142]. Cross-linking of the micelles within the core was hypothesized to 
decrease their CMC values and markedly enhance their stability post 
administration and in non-reductive physiological environments. The PTX 
release from the disulfide cross-linked micelles was significantly slower than 
that from PTX-loaded non-cross-linked micelles (PTX-NCMs) (10 % vs. 18 % 
over 5 h), but was enhanced by adding the reducing agent GSH or N-acetyl 
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cysteine (NAC). The blood circulation times of vehicle and payload were 
investigated by conjugating BODIPY with the polymer and loading DiD 
within the micelles, respectively. The results showed that the BODIPY signal 
of NCMs was rapidly eliminated and fell to the background level within 8 h 
post-injection, while that of DCMs was sustained up to 24 h. Similarly, DiD 
signal of NCMs decreased faster in spite of the initial increase while that of 
the DCMs remained up to 30 h. The toxicity of blank micelles was tested in 
nude mice. At a single dose of 400 mg/kg, all the mice treated with NCMs 
died within 2 h. On the contrary, none of the mice died in the DCM-treated 
group at the same dose. The in vivo anti-tumor activity was further evaluated 
in the subcutaneous human ovarian SKOV-3 tumor bearing mice. At a dose of 
10 mg/kg, PTX-DCMs showed superior tumor growth inhibition and longer 
survival time than PTX-NCMs (median survival time: 28.5 days vs. 32.5 days). 
The anti-tumor activity of PTX-DCMs was further improved when combined 
with NAC. 
 
1.6. Micelle shell-forming materials 
 
In most cases, with limited number of exceptions, PEG is used to form the 
outer layer shell structure of polymeric micelles to provide the stealth 
properties [143,144]. In this section, the advantages of PEG will be reviewed 
to explain why it is the most commonly used micelle shell-forming material. 
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In addition, several drawbacks of PEG and its substituents will also be 
discussed. 
 
1.6.1. Advantages of PEG 
 
PEG is synthesized via ring-opening-polymerization of ethylene oxide. In 
general, it can be synthesized at a wide variety of molecular weights range 
from 400 Da to about 50 kDa with narrow dispersity. The wide range of 
molecular weights makes PEG suitable for different biomedical applications. 
For example, PEG with molecular weight form 20-50 kDa are mostly used to 
conjugate with small molecular drugs and genes to reduce the renal clearance 
time by enhancing the size of the molecules to beyond the renal clearance 
threshold [145]. And PEG with small molecular weight from 1-10 kDa are 
usually attached to large molecules such as proteins, antibodies and 
nanoparticles to provide the stealth property [145]. In addition, the narrow 
dispersity of PEG is a very important characteristic for biomedical 
applications, which can ensure the reproducibility in terms of physical 
properties of PEGylated products, body-residence time and immunogenicity of 
the carrier system [146].  
 
Another advantageous property of PEG is that it can be dissolved in various 
organic solvents, which makes it relative easy to modify the end groups. At the 
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same time, PEG is water soluble. It can enhance the water solubility of 
hydrophobic drugs or nanoparticles when attached to them [147]. Attaching 
PEG to hydrophobic drugs or nanoparticles also can enhance the stability and 
prevent aggregations of these molecules both during storage and in 
applications [145]. An additional advantage of PEG is the highly reactive and 
high functionalities of the end groups. The reactive functionalities of the end 
groups make it an excellent candidate for functionalization onto biomedical 
relevant molecules. For polymeric micelles preparation, diblock copolymers 
are generally synthesized via ring-opening-polymerization using the terminal 
groups such as amine groups or hydroxide groups of PEG as initiators. The 
high functionality of the end groups (~100 %) of PEG can ensure the 
synthesized materials based on PEG are homogeneous without PEG 
homopolymers [147].  
 
Furthermore, the most important advantage of PEG is the stealth property 
when conjugated with drugs or nanoparticles. PEG is well known for its 
inertness in biological conditions, which includes low protein adsorption, low 
activation of contacted cells, low cellular uptake, low degree of cell adhesion, 
low degree of inflammatory activation and low toxicity [147]. Attaching PEG 
to drugs or nanoparticles can not only prevent the interactions with blood 
components, but also minimize enzyme degradation or opsonization followed 
by the removal by reticuloendothelial system (RES), thus, prolonged blood 
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circulation time and enhanced biological activities can be achieved [148]. Also, 
the charge shielding effects of PEGylated cationic molecules and nanoparticles 
could reduce the hemolysis and aggregation of enythrocytes. Similarly, 
conjugating PEG with toxic molecules can significantly reduce the toxicity of 
these molecules by limiting the interactions with normal tissues.  
 
1.6.2. Drawbacks of PEG 
 
One major drawback of PEG is its non-biodegradability. In order to enhance 
the secretion from body, low-molecular-weight PEG is preferable. However, 
PEG oligomers with molecular weight below 400 Da are toxic in human due 
to the propensity to oxidative degradation, which decreases as the molecular 
weight of PEG increases. Therefore, PEG with molecular weight above 400 
Da is preferable for biomedical applications. However, high-molecular-weight 
PEG can accumulate in tissues. It has been reported that the molecular weight 
of PEG is required to be below 40-60 kDa, in order to avoid liver 
accumulation. Unfortunately, 40 kDa molecular-weight PEG is commonly 
used to conjugate with biological active molecules [145].  
 
Apart from non-biodegradability, in some patients, PEG can cause 
immunological response and hypersensitivity reactions when administrated 
intravenously [149,150], orally [151] or dermally [152]. For example, Doxil is 
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a commercial PEGylated liposome formulation of DOX. One study showed 
that the first treatment with Doxil could cause moderate to severe 
hypersensitivity reactions in 45% of patients with solid tumor [150]. The 
mechanism of this immunological response is still unclear and further 
comprehensive studies are required.  
 
Another drawback of PEG is that it can cause accelerated blood clearance 
(ABC) phenomenon [153]. It has been shown that the clearance rate of the 
PEGylated liposome in blood was significantly increased after repeated 
injections of the same formulation. This phenomenon significantly decreases 
the antitumor effects of drug-loaded nanoparticles. In addition, the repeated 
doses of PEGylated carriers have been shown to be uptaken by the Kupffer 
cells inside the liver. This accumulation could cause severe toxicity to the liver 
when delivering highly toxic anticancer therapeutics [147]. Further studies are 
needed to understand the mechanisms of ABC phenomenon.  
 
1.6.3. PEG alternatives 
 
Due to the non-biodegradability of PEG, some biodegradable polymers have 
been designed and synthesized as PEG alternatives. Among them, synthetic 
poly (amino acid)s including poly(glutamic acid) (PGA), 
poly(hydroxyethyl-l-asparagine) (PHEA) and poly(hydroxyethyl-l-glutamine) 
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(PHEG) have attracted the most attentions [145]. These polymers are 
degradable to their corresponding amino acids in vivo. The conjugate between 
PGA and PTX was the first non-PEG based polymer-drug conjugate that 
enters a phase III clinical trial (under the name Opaxia) [154]. Attaching 
PHEA or PHEG to the liposomes could prolong the blood circulation time, 
similar to PEGylated liposomes [155]. More importantly, these liposomes 
could avoid ABC phenomenon caused by PEGylaed liposomes after repeated 
injections [156]. However, these polymers are known to activate the 
complement systems and antigenicity in human.  
 
Another strategy to develop biodegradable PEG alternatives is to synthesize 
polymers containing low-molecular-weight PEG in the backbone via 
biodegradable bond [157,158] or attaching short PEG to the side chain of 
polymers with biodegradable backbone [144,159]. For examples, Lee et al. 
designed and synthesized reduction degradable PEG alternative polymers, 
poly (ethylene oxide sulfide) (PEOS) [157]. These polymers consist of internal 
ethylene oxide oligomer and disulfide bond, which were stable in the 
extracellular environment but were totally degraded under the reductive 
conditions within cells. The results also showed that these polymers were 
non-toxic to HepG2 cell line. In another example, Kim et al. reported diblock 
copolymers with biodegradable polycarbonate backbone for the applications 
as drug carrier [144]. The polymers were synthesized by the 
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ring-opening-polymerization of cyclic carbonate monomers functionalized 
with hydrophilic groups (low-molecular-weight PEG) and hydrophobic groups 
(dodecyl). These polymers were water soluble and thermo responsive. 
Anticancer drug PTX was successfully loaded into the micelles prepared using 
these polymers with small particle size and narrow size distribution. Although 
these polymers are biodegradable, undesirable toxicity can result if PEG with 
molecular weight lower than 400 Da were used [145].  
 
Apart from those biodegradable polymers, some non-biodegradable polymers 
also have been developed as PEG alternatives, such as poly(glycerol) [160], 
poly(2-methyl-2-oxazoline) [161], poly(2-ethyl-2-oxazoline) [161], 
poly(acrylamide) [162], poly(vinylpyrrolidone) [163] and 
poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA) [164,165]. The 
conjugates of PHPMA with drugs have already been used in clinical trials. For 
example, doxorubicin PK1, the conjugate between PHPMA (28 kDa) and 
DOX (8.5 wt.%) was in a phase II clinical trial for the treatment of various 
cancer and was found effective against NSCLC, colorectal cancer, and breast 
cancer [166]. In addition, this conjugate did not show cardio-toxicity, MDR, 
liver or spleen accumulation, immunogenicity and polymer related toxicities in 
these studies [166].  Besides doxorubicin PK1, the conjugates between 25 
kDa PHPMA and DOX galactosamine (7.5 wt.%), carboplatinate (8.5 wt.% 
Pt), and DACH platinate (8.5 wt.%) have also entered phase I/II trials for the 
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treatment of various cancers [164]. Although these polymers showed 
comparable advantages as PEG, their non-biodegradability is still one of the 






















Chapter 2 Hypothesis and Aims 
 
Despite the great progress in diagnostics, prevention and treatment over the 
last decades, cancer is still the second most leading cause of death in the world 
and causes tremendous economic loss. Multidrug resistance (MDR) and the 
presence of cancer stem cells (CSCs) are two of the main reasons causing 
failures in cancer treatment. MDR cancer cells and CSCs are resistant to the 
conventional anticancer treatments, thus inducing cancer recurrence and 
metastasis after treatments. One of the main reasons of causing drug resistance 
in MDR cells and CSCs is the overexpression of P-glycoprotein (P-gp) on the 
cell membranes. Many studies have demonstrated that nanoparticles could 
bypass the P-gp that is overexpressed in MDR cancer cells and CSCs, killing 
these cells more effectively than free drugs. The mechanism is that 
nanoparticles being uptaken by cancer cells through endocytosis, which can 
evade the P-gp efflux pumps. Amongst various nanoparticular formulations, 
polymeric micelles have drawn a lot of attention, due to their unique core-shell 
structure, easy functionalization, and passive targeting to tumor due to the 
enhanced permeability and retention (EPR) effect. Using polymeric micelles 
as drug carriers can enhance the water solubility, prolong blood circulation 
time and reduce non-specific toxicities to normal tissues of free drugs. 
Aliphatic polycarbonates have garnered much attention in the biomedical field 
due to their biodegradability, easy functionalization, and low toxicity in vivo. 
In particular, the organocatalytic ring-opening-polymerization (ROP) 
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methodology recently developed in our laboratory is ideal for the synthesis of 
biomaterials as no toxic metals are involved. Recently, our lab has designed 
and synthesized biodegradable diblock copolymers of polyethylene glycol 
(PEG) and carboxylic acid-functionalized polycarbonate as well as PEG and 
urea-functionalized polycarbonate via living ROP using organocatalysts. 
These polymers could form micelles individually or form mixed micelles 
together. The carboxylic acid and urea pendant groups within micelles cores 
could form hydrogen bonding interactions with each other and were suitable 
for the delivery of various anticancer drugs with special functional groups via 
strong hydrophobic interactions, hydrogen bonding interactions and ionic 
interactions to achieve high drug loading level and enhanced systemic stability. 
These drug-loaded micelles showed effective targeting avtivity to tumor in 
vivo. 
 
It is hypothesized that, polymeric micelles formed from diblock copolymers of 
PEG and biodegradable functional polycarbonates are safe and effective drug 
carriers for the delivery of anticancer drugs for cancer treatment, especially to 
tackle the problems of CSCs and MDR. Particularly, mixed micelles were 
prepared by self-assembly of diblock copolymer of PEG/carboxylic 
acid-functionalized polycarbonate and diblock copolymer of 
PEG/urea-functionalized polycarbonate for the co-delivery of doxorubicin 
(DOX, an anticancer drug) and thioridazine (THZ) that is effective against 
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CSCs for targeting cancer cells and CSCs, respectively. However, one major 
issue of micellular drug delivery system is that drugs are unable to be released 
timely in the tumor or cancer cells. Thus, to exploit the acidic environment in 
the endosomes, pH-sensitive micelles were synthesized for intracellular drug 
release. Two pH-sensitive micelle systems were designed in this study. The 
first one was prepared by self-assembly of diblock copolymers of PEG and 
DOX-conjugated polycarbonate. DOX-conjugated polymers were obtained by 
reacting DOX with aldehyde groups in the polycarbonate to form acid 
cleavable Shiff-base bond. The second micelle system was prepared using 
diblock copolymer of PEG and boronic acid-functionalized polycarbonate as 
well as diblock copolymer of PEG and urea-functionalized polycarbonate for 
the delivery of DOX into 3D tumorspheres. PEG is the gold standard 
shell-forming block for the preparation of polymeric micelles to provide 
stealth property. However, PEG is not biodegradable, and has some other 
drawbacks, which warrant the examination of alternative polymers. To 
optimize the formulation of polymeric micelles, biodegradable hydrophilic 
polycarbonates were designed and synthesized for the replacement of PEG. It 
is postulated that the co-delivery of DOX and THZ in the mixed micelles 
formed from the above mentioned acid- and urea-functionalized polycarbonate 
diblock copolymers will eradicate both cancer cells and CSCs simultaneously, 
the pH-sensitive micelles formed from polymer-DOX conjugates as well as 
boronic acid- and urea-functionalized polycarbonate diblock copolymers will 
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enhance the intracellular drug release and circumvent MDR, and the 
hydrophilic polycarbonate polymers will provide alternatives to PEG for the 
future study in developing new micellular drug delivery systems. To assess the 
hypothesis, the following aims are proposed: 
 
Aim 1: To test the effectiveness of combination therapy using DOX-loaded 
mixed micelles (DOX-MM) and THZ-loaded mixed micelles (THZ-MM) 
prepared by carboxylic acid- and urea-functionalized polycarbonate 
copolymers to target both cancer cells and CSCs using breast cancer cell lines 
BT-474 and MCF-7 cells as cell models. 
 
Aim 2: To enhance the intracellular drug release by preparing pH-sensitive 
micelles formed from the conjugates between DOX and 
PEG/aldehyde-functionalized polycarbonate diblock copolymers via 
Schiff-base bond and evaluate the effectiveness in overcoming MDR using 
drug resistance breast cancer cell line MCF-7/Adr as cell model. 
 
Aim 3: To enhance the intracellular drug release by preparing pH-sensitive 
micelles formed from boronic acid- and urea-functionalized polycarbonate 
copolymers for the delivery of DOX and evaluate the antitumor effectiveness 
on BT-474 2 dimension (2D) monolayer cell model as well as 3 dimension 
(3D) tumorsphere model. 
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Aim 4: To optimize the micellular formulation by designing and synthesizing 
PEG replacing hydrophilic polycarbonate polymers for the future study in 
preparation of novel micellular drug delivery systems. 
 
Studies performed to carry out each specific aim are outlined as follows: In 
chapter 3, an anticancer drug, DOX, and THZ that could specifically target 
CSCs were loaded into mixed micelles prepared using carboxylic acid- and 
urea-functionalized polycarbonate diblock copolymers and delivered 
simultaneously to eradicate both cancer cells and CSCs. The anticancer effects 
and anti-CSCs effects of the combination therapy were evaluated both in vitro 
and in vivo (aim 1). In chapter 4, in order to enhance the intracellular drug 
release, pH-sensitive polymeric micelles were prepared using the conjugates 
between DOX and diblock copolymers of PEG and aldehyde-functionalized 
polycarbonate via pH-responsive Shiff-base bond. The effects of overcoming 
MDR was evaluated in drug resistant cancer cell line MCF-7/Adr (aim 2). In 
chapter 5, another pH-sensitive polymeric micelles system was designed and 
prepared using boronic acid- and urea-functionalized polycarbonate 
copolymers for the delivery of DOX. The anticancer effects of these 
DOX-loaded micelles were evaluated in BT-474 cells both in 2D monolayer 
cell model and 3D tumorsphere model (aim 3). In chapter 6, in order to 
optimize the micellular formulation, hydrophilic polycarbonate polymers were 
designed and synthesized for the replacement of PEG, which is the most 
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widely used micelle shell-forming material. The anti-fouling effect and 
toxicity of these polymers were studied both in vitro and in vivo (aim 4). 






















Chapter 3 Co-delivery of thioridazine and doxorubicin using polymeric 




Amongst various cancers, breast cancer is the most common form of cancers 
diagnosed in women worldwide [167,168]. Despite recent advances in the 
treatment of breast cancer, about 40 % of the patients treated for early-stage 
disease eventually develop recurrence with most of these recurrences being 
distant metastases [169]. One of the key reasons is the presence of cancer stem 
cells (CSCs) [170,171]. CSCs comprise a small sub-population within tumors 
with enhanced capacity for tumor generation, and possess several fundamental 
attributes similar to normal adult stem cells [31,37]. Studies showed that the 
existence of CSCs increased resistance to conventional chemotherapy [31,172]. 
A number of genetic and cellular adaptations have been found to be related to 
the resistance, such as relative dormancy/slow cell cycle kinetics, efficient 
DNA repair, the expression of multidrug-resistance transporters, and resistance 
to apoptosis [11,173]. Although conventional chemotherapies kill the majority 
of cancer cells, the surviving CSCs could reinitiate the tumor, leading to 
cancer relapse and metastasis. Studies demonstrated that conventional 
chemotherapies caused the enrichment of CSCs both in human and animals 
[60,174,175]. Clearly a combination therapy using a conventional 
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chemotherapeutic drug with an agent that can target CSCs may provide a good 
approach to eradicate both cancer cells and CSCs. Successful examples of 
synergistic combination therapies include using parthenolide-loaded 
liposomes/vinorelbine-loaded liposomes [176] and all-trans retinoic 
acid-loaded liposomes/vinorelbine-loaded liposomes [177] to eradicate cancer 
cells and CSCs effectively both in vitro and in vivo. 
 
Thioridazine (THZ), a phenothiazine derivative, is a piperidine antipsychotic 
drug. Recently, it was reported that THZ selectively targeted leukemic CSCs, 
but it had no effect on normal blood stem cells [72]. The selectivity might be 
because THZ antagonized dopamine receptors that were over-expressed on 
leukemic CSCs. In addition, THZ significantly augmented the antitumor 
activity of the antiproliferative agent cytarabine in vitro [72]. Normal 
mammary gland tissue displays low levels of dopamine receptors, while breast 
CSCs (CD44+/CD24-) have a high expression of dopamine receptors [72,178]. 
We hypothesized that THZ could target breast CSCs and achieve a synergistic 
effect with other antiproliferative drugs such as doxorubicin (DOX), which is 
a highly potent and widely used chemotherapeutic agent for the treatment of 
various types of cancers including breast cancer. THZ is well tolerated at low 
concentrations, but an overdose of THZ often leads to uncontrollable 
movement, severe dizziness or fainting, coma, blurred vision and rash, 
irregular heartbeats, and hyperthermic or hypothermic body temperatures 
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[179,180]. Besides, the use of THZ may lead to cardiotoxicity [180]. Similarly, 
DOX causes serious cytotoxicity in normal tissues, such as the induction of 
myelosuppression and cardiotoxicity, hence limiting the maximum tolerated 
dose [181,182]. In addition, DOX can induce drug resistance in cancer cells 
[182]. Therefore, a drug delivery system is necessary to decrease the 
nonspecific toxicity of THZ and DOX for in vivo applications. 
 
As discussed in chapter 1, polymeric micelles are promising delivery carriers 
for anticancer drugs [85,183]. Polymeric micelles with particle size from 10 
nm to 200 nm have been reported to enhance drug accumulation within tumors 
due to the enhanced permeability and retention (EPR) effect of leaky tumor 
tissues [82,184]. Recently, our group reported the synthesis of diblock 
copolymers of poly(ethylene glycol) (PEG) and functional polycarbonates 
with well-controlled molecular weight via metal-free organocatalytic 
ring-opening-polymerization of carbonate monomers using PEG as a 
macroinitiator. The polymers were used to prepare micelles for anticancer drug 
delivery, where the use of non-covalent interactions within the micellar core 
increased drug loading level and enhanced kinetic stability. Specifically, 
mixed micelles, which self-assembled from a diblock copolymer of PEG and 
urea-functionalized polycarbonate (PEG-PUC) and another diblock copolymer 
of PEG and acid-functionalized polycarbonate (PEG-PAC) via hydrogen 
bonding interaction, provided nanosize with narrow size distribution and high 
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loading capacity for anticancer drugs that contain micellar core-interacting 
amine groups. A key example is DOX due to ionic interaction between the 
amine group in DOX and acid group in PEG-PAC [93-95]. DOX-loaded 
mixed micelles also showed higher antitumor efficacy and decreased toxicity 
than free DOX in vivo [94,95]. 
 
THZ also has an amine group and it is anticipated that the 
PEG-PUC/PEG-PAC mixed micelles would be a suitable delivery carrier. In 
this chapter, DOX and THZ were loaded into mixed micelles, and delivered 
simultaneously in vitro and in vivo to target both human breast cancer cells 
and CSCs. DOX-loaded and THZ-loaded mixed micelles (DOX-MM and 
THZ-MM respectively) were characterized for particle size, drug loading and 
in vitro release profiles. Two human breast cancer cell lines BT-474 and 
MCF-7 were employed as models. Side population (SP) cells, rich in CSCs, 
were sorted by flow cytometry from both cell lines. The antiproliferative 
effects of single formulation or the combination of DOX-MM and THZ-MM 
on sorted SP cells, non-side population (NSP) cells and unsorted cells were 
tested. Furthermore, the antitumor activity of the formulations was tested in 
nude mice bearing BT-474 cancer xenografts to evaluate the feasibility of such 




3.2. Materials and Methods 
 
3.2.1. Materials 
The synthesis procedures for preparation of 
5-methyl-5-benzylcarboxyl-1,3-dioxan-2-one (MTC-OBn) and 
5-methyl-5-(phenylureaethyl)carboxyl-1,3-dioxan-2-one (MTC-urea) 
carbonate monomers followed the methods reported previously [93,94,185]. 
Doxorubicin-hydrochloride (DOX-HCl), thioridazine-hydrochloride 
(THZ-HCl), Hoechst 33342 and all other reagents were purchased from 
Sigma-Aldrich (St. Louis, MO, U.S.A.) unless otherwise specified. 
Anti-human CD44-FITC and CD24-PE monoclonal antibodies and their 
isotype controls were purchased from Abcam (Hong Kong). Matrigel was 
bought from Becton Dickinson (San Jose, CA, U.S.A.). 17β-Estradiol pellets 
were obtained from Innovative Research of American (Sarasota, FL, U.S.A.). 
Collagenase III was purchased from i-DNA (Singapore). Human breast cancer 
cell lines BT-474 and MCF-7 were purchased from ATCC (Manassas, VA, 
U.S.A.). Cells were cultured in RPMI-1640 medium (Lonza, Singapore) 
supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 
100 U/mL streptomycin at 37 °C in 5% CO2 atmosphere. 
 
3.2.2. Synthesis and characterization of urea-functionalized (PEG-PUC) and 
acid-functionalized (PEG-PAC) diblock copolymers 
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The diblock polycarbonate copolymers functionalized with 10 kDa PEG/acid 
and 10 kDa PEG/urea were synthesized by Dr. Victor Ng in IBN. The 
polymers were synthesized via metal-free organocatalytic 
ring-opening-polymerization of functionalized methylcarboxytrimethylene 
carbonate (MTC) using 10 kDa mPEG as macroinitiator. The details of the 
syntheses and molecular characterization are provided in Appendix 1. 
 
3.2.3. Preparation and characterization of micelles (Scheme 3.1) 
DOX-loaded micelles were prepared by a membrane dialysis method as 
described in our previous report [93]. Briefly, DOX-HCl (5 mg) was dissolved 
in N, N-dimethylacetamide (DMAc, 1.5 mL) containing three mole 
equivalents of triethylamine (3.84 µL). To this solution was added PEG-PAC 
(4.55 mg) and PEG-PUC (5.45 mg) in 0.5 mL of DMAc (PEG-PAC/PEG-PUC: 
1:1 molar ratio). The resulting solution was added dropwise to 10 mL of DI 
water while being sonicated for 2 min (130 W) using probe-based sonicator 
(Vibra Cell VCX 130). The free DOX was removed by dialysis against DI 
water for 48 h using a dialysis bag with molecular weight cut-off (MWCO) of 
1000 Da (Spectra/Por 7, Spectrum Laboratories Inc.), and water was changed 
3 times at 3, 6 and 24 h. The solution inside the dialysis bag was then collected 






Scheme 3.1. Polymer synthesis and micelle preparation 
 
THZ-loaded micelles were prepared through a thin film hydration method. 
Briefly, THZ-HCl (3 mg) was dissolved in acetonitrile (1 mL) containing three 
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mole equivalents of triethylamine (3.28 µL). To this solution was added 
PEG-PAC (4.55 mg) and PEG-PUC (5.45 mg) in 1 mL of acetonitrile 
(PEG-PAC/PEG-PUC: 1:1 molar ratio). The acetonitrile was evaporated by 
using a rotary vacuum evaporator at 50 °C for 30 min. The lipid film was 
hydrated with phosphate-buffered saline (PBS, pH 7.4) by sonication in water 
bath for 30 min at 50 °C to get a clear micelle solution, which was then 
dialyzed against DI water for 48 h using a dialysis bag with MWCO of 1000 
Da (water was changed 3 times at 3, 6 and 24 h). The solution was collected 
and lyophilized to obtain THZ-MM. 
 
The particle size and size distribution of the micelles was determined using a 
DTS Zetasizer Nano (Malvern Instruments, Worcestershire, UK). The drug 
loading of the micelles was quantified using UV-Vis spectrophotometer (UV 
2501PC Shimadzu, Japan). A known amount of drug-loaded micelles was 
dissolved in DMSO and the absorbance of the solution was measured at 480 
nm to determine DOX content and 320 nm to determine THZ content. The 
standard curves of DOX and THZ in DMSO were constructed to determine the 
drug concentrations. The drug loading was then calculated using the following 
formula: drug loading % = (mass of drug loaded in micelles/mass of 
drug-loaded micelles) × 100%. 
 
3.2.4. In vitro drug release 
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The in vitro release of DOX from micelles was determined by dialysis against 
PBS at pH 7.4 at 37 °C. Briefly, DOX-loaded micelle solution (200 mg/L, 2 
mL) was placed inside a membrane dialysis bag with MWCO of 2 kDa. The 
bag was immersed in 30 mL of release medium (PBS, pH 7.4) while being 
shaken at 100 rpm. At the predetermined time points, 1 mL of the release 
medium was collected and the UV absorbance was recorded at 480 nm using 
the UV-Vis spectrophotometer to determine the content of DOX. Fresh PBS 
(pH 7.4, 1 mL) was added to the release medium at the same time. The same 
method was used for the in vitro release study of THZ from micelles. The THZ 
content was determined at 320 nm. 
 
3.2.5. Intracellular distribution 
DOX-loaded micelles were used to investigate intracellular distribution in 
both BT-474 and MCF-7 cell lines. The cells were seeded at a density of 1×105 
cells/well onto a 4 well-cover slip borosilicate glass chamber (NUNC). After 
24 h, the medium was replaced with cell culture medium containing free DOX 
or DOX-loaded micelles (10 µM equivalent DOX concentration) and the cells 
were incubated for another 2 h at 37 °C. The medium was removed and the 
cells were washed three times with cold PBS followed by staining with 
Hoechst 33258 solution for 30 min. The cells were washed again three times 
with PBS and then observed using a confocal laser scanning microscope 
(CLSM, Olympus FV300, Japan) under the same conditions. 
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3.2.6. Sorting and identification of SP cells (cancer stem cells) 
Breast CSCs were sorted by a side population (SP) assay from both BT-474 
and MCF-7 cell lines. Briefly, cells harvested at about 85% confluence were 
suspended in RPMI-1640 supplemented with 2% FBS at a density of 1×106 
cells/mL, and pre-warmed at 37 °C for 10 min. The cells were stained with 
Hoechst 33342 at a concentration of 5 µg/mL with or without 100 µM 
verapamil-HCl for 90 min at 37 °C. The dye was unable to enter SP cells, but 
it stained the cells in the presence of verapamil. The medium was then 
removed by centrifugation at 4 °C at 1000 rpm for 5 min and the cells were 
suspended in cold PBS at 1 × 106 cells/mL, followed by filtering through a 
40-µm cell strainer to get single cell suspensions. The cells were stained with 
1 µg/mL propidium iodide to exclude dead cells, and then analysed and sorted 
on a FACSDiva (Becton Dickinson, San Jose, CA, U.S.A.) by using a 
dual-wavelength analysis (blue, 420-470 nm; red, 660-680 nm) [47]. 
 
Immuno-staining was used to identify the phenotype of breast CSCs. The 
freshly sorted SP subpopulation cells were suspended in cold PBS and then 
stained with anti-human CD44-FITC and CD24-PE or their appropriate 
isotype controls on ice for 30 min at concentrations recommended by the 
manufacturer. The cells were washed 3 times with cold PBS, suspended in 400 




3.2.7. MTT assay 
At the end of the treatment, the drug-containing medium was removed and 
100 µL of growth medium mixed with 20 µL MTT solution (5 mg/mL) was 
added into each well. The plates were incubated at 37 °C, 5% CO2 for 4 h. The 
medium was then carefully removed and 150 µL of DMSO was added. The 
plates were agitated for 10 min to dissolve the formazan crystals. The 
absorbance at 490 nm was recorded on a microplate reader (TECAN, 
Switzerland). Cell viability was calculated by using the following formula: 
viability % = (A490nm for the treated cells-A490nm for the blank without 
cells)/(A490nm for the non-treated control cells-A490nm for the blank without 
cells) × 100, where A490nm is the absorbance value at 490 nm [93,94]. 
 
3.2.8. Effects of various drug formulations on SP and NSP cells 
In order to investigate the effects of various drug formulations on the breast 
cancer stem cells, SP and NSP cells freshly sorted from BT-474 and MCF-7 
cells were seeded onto 96-well plates at a cell density of 2000 cells/well, and 
grown at 37 °C in the presence of 5% CO2. After incubating for 48 h, the 
medium was removed and fresh medium containing 5 µM free THZ, 5 µM 
THZ-MM, 0.3 µM free DOX, 0.3 µM DOX-MM, a mixture of 5 µM free THZ 
and 0.3 µM free DOX or a mixture of 5 µM THZ-MM and 0.3 µM DOX-MM 
were added. The inhibitory effects of various formulations were assessed using 
MTT assay described in Section 3.2.7. 
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3.2.9. Effects of THZ (or THZ-MM) with and without DOX (or DOX-MM) on SP 
cells in non-isolated cells 
The inhibitory effects of free THZ and THZ-MM on SP cells (cancer stem 
cells) were evaluated in non-isolated BT-474 and MCF-7 cells. The cells were 
cultured in a 25 cm2 cell culture flask (NUNC) at a density of 5.0 × 105 
cells/mL at 37 °C, 5% CO2. After 24 h, the medium was replaced with fresh 
medium containing 5 µM free THZ, 5 µM THZ-MM, 0.3 µM free DOX, 0.3 
µM DOX-MM, a mixture of 5 µM free THZ and 0.3 µM free DOX or a 
mixture of 5 µM THZ-MM and 0.3 µM DOX-MM. After treated for 48 h, the 
cells were harvested by trypsinization and washed with PBS. The cells were 
then suspended in RPMI-1640 medium containing 2% FBS at 1 × 106 
cells/mL, and the population of SP cells (CSCs) was then analyzed as 
described in Section 3.2.6. 
 
3.2.10. Cytotoxicity of various drug formulations against BT-474 and MCF-7 
cell lines 
To measure the inhibitory effects of DOX, DOX-MM, THZ and THZ-MM on 
BT-474 and MCF-7 cells, the cells harvested at about 85% confluence were 
seeded onto 96-well plates at 5000 cells/well and allowed to grow for 24 h. 
Fresh medium containing blank micelles, free DOX, free THZ, DOX-MM and 
THZ-MM at various concentrations was used to replace the used medium, and 
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the cell viability was tested by the MTT assay as described above after 
incubating for 48 h. 
 
The effect of combination therapy using DOX and THZ was evaluated on 
BT-474 and MCF-7 cells. The cells were seeded onto 96-well plates at 5000 
cells/well and allowed to grow for 24 h. The used medium was then replaced 
with fresh medium containing a mixture of free DOX and free THZ or a 
mixture of DOX-MM and THZ-MM. The concentration of free DOX or 
DOX-MM varied from 0.3 to 10 µM, but that of THZ or THZ-MM was fixed 
at 5 µM. After incubation for 48 h, the cytotoxicity of the combination therapy 
was measured by the MTT assay. 
 
3.2.11. In vivo antitumor efficacy 
Female BALB/c nude mice were provided by Singapore Biological Research 
Center (BRC) at 6 weeks of age (20-22 g). All animal studies were adhered to 
protocols approved by the Singapore BRC’s Institutional Animal Care and Use 
Committee. BT-474 cells (1 × 107) were suspended in 100 µL of Matrigel and 
subcutaneously injected into the right flank of female BALB/c nude mice. 
Estradiol pellet (0.72 mg/pellet, 60 days release) was subcutaneously 
administered into mice one day before the inoculation. Once the tumor volume 
reached about 200 mm3 on the 9th day (recorded as day 0), the mice were 
randomly divided into 7 groups (10 animals per group): group 1 for 0.9% 
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saline as control, group 2 for free THZ, group 3 for THZ-MM, group 4 for free 
DOX, group 5 for DOX-MM, group 6 for the mixture of free DOX and free 
THZ, and group 7 for the combination treatment with DOX-MM and 
THZ-MM. The dose of both DOX and THZ in all formulations was 5 mg/kg. 
The formulations were given to mice via i.v. injection at day 0, 3, 6 and 10. At 
the predetermined time points, mice were weighed and tumor size was 
measured with a Vernier caliper. The tumor volume was calculated using the 
following formula: Tumor volume = length×width2/2. 
 
3.2.12. Analysis of CSCs in tumors after treatments 
At the end of the treatment, tumors were collected from all groups and washed 
3 times by PBS. After being cut into 1 mm3 of small pieces, enzymatic 
digestion was performed by using collagenase III at 37 °C for 2 h. To obtain 
single cells, cell suspension was filtered through a 40-µm cell strainer. Cells 
were washed 3 times with PBS and then re-suspended in 100 µL cold PBS 
followed by staining with anti-human CD44-FITC and CD24-PE or their 
appropriate isotype controls on ice for 30 min. After washed 3 times with cold 
PBS, the cells were suspended in 400 µL of cold PBS and then the percentage 






All experiments were performed at least 3 times and presented as mean ± 
standard deviation (SD). The differences in study groups were evaluated using 
Student’s t-test, which were considered statistically significant if p<0.05, and 
highly significant if p< 0.01. 
 
3.3. Results and discussion 
 
3.3.1. Synthesis and characterization of monomers and polymers 
MTC-OBn monomer was obtained directly by the ring closing of 
commercially available 2,2-bis(methylol)propionic acid. MTC-OH was 
subsequently made by deprotection of the benzyl protecting group via 
hydrogenolysis. Separately, MTC-urea was obtained by coupling of the 
activated acid chloride of MTC-OH, i.e. MTC-Cl, with phenylureaethanol 
[93,94]. The syntheses of urea- and acid-functionalized polycarbonates were 
achieved by organocatalytic ring-opening-polymerization (ROP). This 
approach is simple and attractive for synthesizing biomaterials as no toxic 
metals are involved, and the by-products easily removed by precipitation. 
Furthermore, the molecular structure of the desired polymers can be well 
controlled [94]. From 1H NMR analysis, the repeating units of MTC-OBn and 
MTC-Urea on mPEG (10 kDa) were determined to be 12 and 13, respectively. 
The narrow monomodal polydispersity indices for both polymers are 
indicative of well controlled polymerization.  
68 
 
3.3.2. Characterization of drug-loaded mixed micelles 
The particle sizes of DOX-MM and THZ-MM were 89.6 ± 1.8 nm and 77.0 ± 
0.7 nm, respectively. Both mixed micelles had a narrow size distribution (PDI: 
0.10 ± 0.02 for DOX-MM and 0.10 ± 0.01 for THZ-MM) as shown in Fig. 3.1. 
The nanosize with narrow size distribution indicates that these micelles are 
desirable for tumor accumulation and biodistribution [94]. The drug loading 






Fig. 3.1. Representative particle size distribution of (A) DOX-MM and (B) 
THZ-MM, measured by dynamic light scattering. 
 
3.3.3. In vitro drug release 
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The in vitro release of DOX and THZ from the micelles was investigated in a 
simulated physiological environment (PBS, pH 7.4, 37 ºC). As shown in Fig. 
3.2, both DOX and THZ had similar release profiles, and the release was 
sustained over 8 h. Around 40% of DOX molecules and 54% of THZ 
molecules were released from their respective micelles at 8 h. After 8 h, the 
releases of both DOX and THZ were too slow to be detected. The incompelet 
drug releases in both types of micelles maybe due to the strong ionic 
interactions, hydrogen bonding interactions and hydrophobic interactions 
within micelle cores. Nonetheless, drug release is expected to accelerate inside 
























Fig. 3.2. In vitro release of DOX and THZ from DOX-MM and THZ-MM 
respectively in PBS (pH 7.4) at 37°C. 
 
3.3.4. Intracellular distribution of drug-loaded micelles 
The distribution of DOX-MM inside BT-474 and MCF-7 cells was studied 
using confocal microscopy. As shown in Fig. 3.3, in both BT-474 and MCF-7 
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cells, the free DOX molecules were mainly located in the nucleus after 
incubation for 2 h, whereas they were found primarily in the cytosol when 
delivered by the micelles. This occurrence was due to the fact that free DOX 
diffused into the cells through passive diffusion without a release process 
involved, whereas DOX-MM was internalized by non-specific endocytosis 
and it took time for DOX to release from the micelles. A similar phenomenon 













Fig. 3.3. Confocal microscopic images of BT-474 cells (A) or MCF-7 cells (B) 
incubated with free DOX or DOX-MM at 37 °C for 2 h. The concentration of 
DOX and DOX-MM was 10 µM. Scale bar: 20 µm. 
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3.3.5. SP sorting and identification 
The breast CSCs were sorted and purified by a side population assay [47]. SP 
cells are a small population of cells that are located in the lower left quadrant 
on a density dot plot. These cells are weakly stained when Hoechst 33342 dye 
was used, because the ATP-binding cassette transporter (ABC transporter) 
transmembrane proteins in the membrane of SP cells can pump out the dye. As 
illustrated in Fig. 3.4, the percentage of breast CSCs (SP cells) was 1.4 % for 
BT-474 cells and 2 % for MCF-7 cells. As a negative control, the cells were 
co-treated with an ABC transporter inhibitor (verapamil), and the population 
of cancer stem cells was found to be significantly reduced. To measure the 
purity of SP cells, freshly sorted SP cells were labeled with anti-human CD44 
and CD24 antibodies. As shown in Fig. 3.5, the purity was 99.7 % and 97.9 % 
for BT-474 and MCF-7 cells, respectively. The CSCs were characterized with 
high expression of CD44 and low expression of CD24, which was consistent 
with the previous findings in human breast cancer cells [7]. 
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Fig. 3.4. Identification and sorting of CSCs (side population cells – SP cells) 
in BT-474 (A) and MCF-7 (B) cells. Images of A1 and B1 were obtained from 
the specimens stained with Hoechst 33342 in the presence of verapamil; A2 



























Fig. 3.5. Identification of phenotype for CSCs (SP cells) sorted from BT-474 
cells (A) and MCF-7 cells (B). A1 and B1 were from the cells stained with 
isotype controls; A2 and B2 were from the cells stained with anti-human 




3.3.6. Effect of drug treatments on sorted cancer stem (SP) cells and sorted NSP 
cells 
To investigate the inhibitory effects of THZ, DOX and their combination on 
SP and NSP cells, SP and NSP cells were sorted from both BT-474 and MCF-7 
cells. Drug sensitivity was measured by MTT assay. As shown in Fig. 3.6, free 
THZ (5 µM) and THZ-MM (5 µM) showed higher inhibitory effects on SP 
cells than on NSP cells especially in BT-474 cells. This indicated that both free 
THZ and THZ-MM were more potent in suppressing the growth of SP cells 
than sorted NSP cells. The reason may be because the breast CSCs express 
higher levels of dopamine receptor and the selectively suppression effect of 
THZ to the CSCs is via the dopamine receptor antagonism [72,178]. The 
mechanism of THZ action to inhibition the CSCs need to be further 
investigated in the future. 
 
In contrast, the antiproliferative effect of free DOX (0.3 µM) on SP cells was 
significantly lower than that of sorted NSP cells, which was consistent with 
reported findings that CSCs were more resistant to chemotherapeutic drugs 
than NSP cancer cells [68,188]. For example, in BT-474 cells, the viability of 
SP cells was 60.3 ± 2.9 % after treatment with free DOX (0.3 μM), whereas it 
was 49.8 ± 3.4 % for NSP cells (Fig. 3.6A1). When DOX-MM was used, the 
antiproliferative effect of DOX against SP cells was similar to that against 
NSP cells (Fig. 3.6A2 and B2). As compared with free DOX or DOX-MM 
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alone, the antiproliferative effect on SP cells was markedly increased after 
treatment with a mixture of free DOX and free THZ or a mixture of DOX-MM 
and THZ-MM, showing that THZ or THZ-MM was able to augment the 






























































































































































Fig. 3.6. Effects of various drug formulations on the CSCs (sorted SP cells) 
and cancer cells (sorted NSP cells). THZ: 5 µM; DOX: 0.3 µM. (A) BT-474 
cells; (B) MCF-7 cells. ** p<0.01. 
 
3.3.7. Effect of drug treatments on the SP cells in non-isolated cells 
In order to evaluate the effects of different formulations on the population of 
breast CSCs in non-isolated cancer cells, the non-isolated BT-474 and MCF-7 
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cells were treated with various formulations, and the percentage of CSCs was 
analyzed by the SP assay. As shown in Fig. 3.7, in BT-474 cells, there were 1.4 
± 0.1 % SP cells. After treatment with free THZ (5 µM) and THZ-MM (5 µM), 
the percentage of SP cells significantly decreased to 0.1 ± 0 % and 0.3 ± 0.1 %, 
respectively, indicating that both free THZ and THZ-MM were potent against 
CSCs. In contrast, after treatment with free DOX (0.3 µM) or DOX-MM (0.3 
µM), the percentage of SP cells was increased to 3.1 ± 0.2 % and 2.5 ± 0.1 % 
respectively. The reason was probably because DOX was more effective in 
inhibiting cancer cells than CSCs, and also exposure to chemotherapeutic 
drugs could sometimes increase the population of CSCs in the cancer cells 
[175]. The increasing percentage of CSCs after treatment with DOX suggested 
that a combination therapy using DOX with a CSCs targeting drug would be 
necessary and beneficial. As compared with the free DOX or DOX-MM alone, 
the treatment with DOX/THZ mixture or DOX-MM/THZ-MM mixture led to 
a significantly decreased number of SP cells (0.9 ± 0 % for DOX/THZ and 0.4 
± 0.1 % for DOX-MM/THZ-MM), which indicated that the combination 
therapy with free THZ or THZ-MM was effective in reducing the number of 
cancer stem cells. The similar results were also observed in MCF-7 cells.  
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Fig. 3.7. Percentage of SP cells in unsorted BT-474 (A) or MCF-7 (B) cells 
after treated with free THZ (5 µM), THZ-MM (5 µM), free DOX (0.3 µM), 
DOX-MM (0.3 µM), a mixture of free THZ (5 µM) and free DOX (0.3 µM) 
and a mixture of THZ-MM (5 µM) and DOX-MM (0.3 µM) for 48 h. 
 
3.3.8. Effect of drug treatments on non-isolated cancer cells 
The inhibitory effects of THZ, THZ-MM, DOX, DOX-MM and their 
combinations were investigated on non-isolated BT-474 and MCF-7 cells. As 
shown in Fig. 3.8A and B, both free THZ and THZ-MM had an inhibitory 
effect on BT-474 and MCF-7 cell lines with similar IC50 values (BT-474: 6.58 
and 7.05 µM respectively; MCF-7: 21.7 and 24.0 µM respectively). THZ can 
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specifically target the dopamine receptor, and breast cancer cells were reported 
to express a certain level of dopamine receptor [178]. When the concentrations 
of free THZ or THZ-MM increased to 20 and 40 µM, all BT-474 cells were 
killed after 48 h of incubation. A similar phenomenon was also found on 
MCF-7 cells when the concentration of free THZ and THZ-MM was 40 µM. 
These results indicated that THZ and THZ-MM had antiproliferative effects on 
both CSCs and non-isolated cancer cells. 
 
As shown in Fig. 3.8C and D, both DOX and DOX-MM significantly 
inhibited the proliferation of non-isolated cancer cells with IC50 values of 
2.57 vs. 3.31 µM on BT-474 and 1.50 vs. 3.24 µM on MCF-7. The cytotoxic 
effects increased with increasing concentration. Both cell lines were more 
sensitive to free DOX than DOX-MM, which was due to slow release of DOX 
from DOX-MM. However, our previous studies showed that the mixed 
micelles were able to enhance the accumulation of drug within tumors due to 
EPR effect [95]. Therefore, it is expected that DOX-MM and THZ-MM would 
have a stronger in vivo antitumor effect than free DOX and THZ respectively. 
 
The blank micelles showed no antiproliferative effects to either of the cell 
lines even at a high concentration of 400 mg/L (Fig. 3.9), which suggested that 
the cell cytotoxicity of THZ-MM or DOX-MM was solely due to the effect of 
THZ or DOX. 
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To investigate whether THZ influences the antiproliferative effect of DOX, 
BT-474 and MCF-7 cells were treated with a mixture of free DOX and free 
THZ or a mixture of DOX-MM and THZ-MM at various DOX concentrations 
and THZ concentration of 5 µM for 48 h. As shown in Fig. 3.9A1 and A2, in 
BT-474 cells, at all DOX concentrations tested, the combination groups had 
significant lower cell viability than that of single drug-treated groups. Similar 
results were also found in MCF-7 cells (Fig. 3.10 B1 and B2). These results 




















































































































































Fig. 3.8. Viability of BT-474 (A, C) and MCF-7 cells (B, D) after incubation 






































































Fig. 3.9. Viability of BT-474 (A) and MCF-7 cells (B) after incubation with 




























































































































































Fig. 3.10. Viability of BT-474 (A) and MCF-7 cells (B) after incubation with 
DOX/THZ combination or DOX-MM/THZ-MM combination for 48 h. The 
concentration of DOX or DOX-MM were 10, 2.5 and 0.3 µM; the 





3.3.9. In vivo antitumor activity 
Fig. 3.11A describes the therapeutic efficacy following the treatment with 
various formulations in nude mice bearing BT-474 xenografts. As compared 
with free DOX, THZ, THZ-MM or DOX-MM alone, the combination 
formulations showed significantly stronger tumor inhibition effects, which 
was in agreement with the results obtained from in vitro studies. In addition, 
the combination therapy with the mixture of DOX-MM and THZ-MM showed 
higher antitumor effect than the mixture of free DOX and free THZ, and 
DOX-MM and THZ-MM demonstrated higher efficacy than free DOX and 
free THZ, respectively. This is due to the EPR effect of micelles in tumor 
tissues. 
 
Fig. 3.11B shows the changes in the body weight of mice during the treatment. 
The body weight loss in the mice treated with free DOX or the combination of 
free DOX and free THZ was significantly higher than that in the mice treated 
with DOX-MM or the combination of DOX-MM and THZ-MM. This finding 
indicated that the mixed micelles were capable of suppressing the toxicity of 
free DOX. The mice treated with free THZ or THZ-MM did not show 
significant weight loss during the whole treatment. However, after the 
administration of free THZ or the combination of free THZ and free DOX, all 
mice had uncontrollable movement or were in coma. On the contrary, these 
symptoms were not observed in mice treated with THZ-MM or the mixture of 
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THZ-MM and DOX-MM, implying that the THZ-MM formulation was better 
tolerated than free THZ. 
 
3.3.10. Inhibition effect of THZ and THZ-MM on CSCs in vivo 
To investigate the inhibition effect of THZ and THZ-MM on CSCs in vivo, the 
population of CSCs (CD44+/CD24-) recovered from the tumors at the end of 
the treatments was analyzed. As shown in Fig. 3.10C, the percentage of CSCs 
from mice treated with THZ or THZ-MM was significantly lower than that of 
the control group. The percentage of CSCs in the tumors treated with 
THZ-MM was lower than that in the tumors treated with THZ (1.03 ± 0.15 % 
vs. 2.27 ± 0.21 %), attributing to the EPR effect of micelles in vivo. In contrast, 
after the treatment with free DOX, the percentage of CSCs was much higher 
than that of the control group, which was consistent with findings reported by 
others [175, 189]. This result also suggested the necessity of using a drug that 
can kill CSCs in combination with DOX. As compared with the free DOX or 
DOX-MM alone, in the tumors treated with the combination of free DOX and 
free THZ or the combination of DOX-MM and THZ-MM, the percentage of 
CSCs was significantly decreased. These results further demonstrated that the 
combination therapy with free THZ or THZ-MM was effective in decreasing 
the population of CSCs. Although THZ-MM had lower antitumor efficacy 
than DOX-MM, the combination therapy of THZ-MM and DOX-MM 
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achieved a greater antitumor effect than DOX-MM (Fig. 3.11A). In addition, 
the combination therapy may also prevent relapse and tumor metastasis as 














































































































































































































Fig. 3.11. Effects of combination therapy in vivo. (A) Antitumor activity of 
various formulations in nude mice bearing BT-474 xenografts: 0.9% saline, 
free THZ (5 mg/kg), THZ-MM (5 mg/kg), free DOX (5 mg/kg), DOX-MM (5 
mg/kg), a mixture of free DOX (5 mg/kg) and free THZ (5 mg/kg) and a 
mixture of DOX-MM (5 mg/kg) and THZ-MM (5 mg/kg); (B) Changes of 
mouse body weight during the treatments; (C) Percentage of cancer stem cells 
(CD44+/CD24-) in cells obtained from tumors at the end of the treatments. a, 
p<0.01, vs. control; b, p<0.05, vs. THZ; c, p<0.05, vs. DOX; d, p<0.01, vs. 
DOX; e, p<0.01, vs. THZ; f, p<0.01, vs. DOX-MM or THZ-MM; g, p<0.05, vs. 





DOX and THZ have been successfully loaded into micelles using a polymeric 
mixture of PEG-PUC and PEG-PAC. The drug-loaded micelles have sizes 
below 100 nm and narrow size distribution as well as high drug loading levels. 
Both THZ and THZ-MM are capable of selectively inhibiting breast CSCs 
when acting alone or when combined with DOX or DOX-MM. In addition, 
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THZ and THZ-MM show antiproliferative effect on non-isolated breast cancer 
cells and enhance the antitumor effects of DOX and DOX-MM in vitro. In 
nude mice bearing BT-474 xenografts, DOX-MM and THZ-MM suppress 
tumor growth more effectively than free DOX and free THZ, respectively. 
Importantly, THZ-MM significantly decreases the population of CSCs in the 
tumors, and the co-delivery of DOX-MM and THZ-MM achieves stronger 
antitumor efficacy when compared to DOX-MM and THZ-MM alone. 
Therefore, the combination therapy of DOX-MM and THZ-MM can be a 
potential strategy for the treatment of breast cancer by targeting both cancer 















Chapter 4 DOX conjugated pH-sensitive polycarbonate micelles to 




In chapter 3, acid-functionalized and urea-functionalized diblock copolymers 
have been developed for the preparation of mixed micelles as drug carriers for 
the co-delivery of DOX and THZ. The combination therapy using DOX-MM 
and THZ-MM could effectively target cancer cells and CSCs both in vitro and 
in vivo for the treatment of breast cancer.  
 
Until now, most of the micellar systems reported so far in the literature have a 
premature drug release before they reach the tumor site, and are unable to 
provide timely intracellular drug release after they enter tumor cells via 
endocytosis, which affects the biological activity of the enclosed anticancer 
drugs [190-193]. To prevent drug leakage before reaching the diseased sites, 
drug-polymer conjugates were reported to form micelles with the drug in the 
core [113,194]. In addition, due to the slightly acidic condition (pH 6.8-7.2) of 
the tumor site and the higher acidity in the endosomal environment (pH 
5.0-6.5) as compared to the extracellular environment, pH-sensitive 
drug-conjugated micelles based on the acid-labile linkages such as hydrazone 





As discussed in chapter 1, the development of multidrug resistance (MDR) is a 
major obstacle in cancer chemotherapy, and the overexpression of the efflux 
P-glycoprotein (P-gp) in the cellular membrane is one of the main reasons that 
cause drug resistance [198,199]. It was reported that the nano-sized particles 
such as micelles and liposomes can bypass the P-gp efflux system and 
promote the intracellular accumulation of chemotherapy drugs [200-202]. 
Furthermore, pH-sensitive micelles are expected to provide fast intracellular 
drug release and bring the intracellular drug concentration to a sufficiently 
high level to exceed the efflux capacity of P-gp [203,204]. 
 
Aliphatic polycarbonates have garnered much attention in the biomedical field 
due to their biodegradability and low toxicity in vivo [205,206]. In addition, 
compared to other polyesters such as polylactide, various functional groups 
can be introduced into polycarbonates for specific biomedical applications 
[207]. In particular, the organocatalytic ring-opening-polymerization (ROP) 
methodology recently developed in our laboratory is ideal for synthesis of 
biomaterials as no toxic metals are involved [208]. By using this method, a 
number of functional polycarbonates have recently been designed and 
synthesized for drug [93,94] and gene [209,210] delivery as well as cell 
expansion [211].  
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In this chapter, diblock copolymers of poly(ethylene glycol) (PEG) and 
polycarbonate with aldehyde groups were synthesized via organocatalytic 
ring-opening-polymerization, and DOX was then conjugated to the aldehyde 
groups of polycarbonate through the primary amine group of DOX by forming 
the acid-labile Schiff-base linkage, which is known to be stable at pH 7.4 but 
readily cleavable at the endolysosomal pH [192,212,213]. DOX-conjugated 
diblock copolymers self-assembled into micelles, which would be stable in the 
extracellular environment (pH 7.4), while in the acidic endolysosomal 
environment DOX would be cleaved from the micelles. The structures of the 
polymers and the conjugation between the polymers and DOX were 
characterized by 1H NMR, GPC and IR. The size, size distribution, stability 
and in vitro release at different pH of the micelles were analyzed. In addition, 
the cellular uptake and in vitro anti-tumor activity of DOX-conjugated 
micelles were also investigated in both drug-sensitive and drug-resistant 
MCF-7 cells. Such a pH-sensitive micellar anti-cancer drug delivery system 
can provide effective anti-tumor chemotherapy, particularly in the case of 
MDR tumor cells. 
 
4.2. Materials and Methods 
 
4.2.1. Materials 
All reagents were purchased from Sigma-Aldrich and used as received unless 
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otherwise noted. Fetal bovine serum (FBS) was purchased from Invitrogen 
Corporation. Human breast cancer MCF-7 cell line (American Type Culture 
Collection, U.S.A.) and doxorubicin-resistant MCF-7/Adr cells (Obtained 
from Dr. Rachel Ee, Department of Pharmacy, National University of 
Singapore) were cultured in RPMI-1640, supplemented with 10% FBS, 100 
U/mL penicillin and 100 U/mL streptomycin at 37 °C in 5% CO2 atmosphere. 
The MCF-7/Adr cells were cultured in RPMI-1640 with 2 µM DOX to 
maintain the drug-resistance phenotype, and transferred to RPMI-1640 
without DOX a week before experiments.  
 
4.2.2. Synthesis and characterization of aldehyde functionalized monomer and 
polymer (Scheme 4.1) 
The aldehyde functionalized monomer and polymers were synthesized by our 
collaborator Dr. Daniel J. Coady in IBM Almaden Research Center. The 
polymers were synthesized via metal-free organocatalytic 
ring-opening-polymerization of functionalized MTC using mPEG as 
macroinitiator. Two diblock copolymers with 5 kDa PEG (PC-1) and 8 kDa 
PEG (PC-2) were synthesized. The details of the syntheses and molecular 
characterization are provided in Appendix 2. 
 
4.2.3. Conjugation of DOX and polymers 
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DOX-HCl (21 mg) was dissolved in 1 mL of DMSO in the presence of an 
equivalent of TEA. This solution was added dropwise to a stirred solution of 
PC-1 (15 mg, in 1 mL DMSO) or PC-2 (20 mg, in 1 mL DMSO). The reaction 
was allowed to proceed at room temperature in the dark. After 16 h, the 
product was dialyzed against DI water (pH adjusted to 7.4 by NaOH solution) 
using a dialysis membrane tube with molecular weight cut-off (MWCO) of 2 
kDa for 5 days to remove DMSO and unbound DOX. The solution was 
freeze-dried to yield the DOX-conjugated polymers. The DOX content was 
analyzed using a UV-Vis spectrophotometer in DMSO at 480 nm. A standard 
curve was constructed to determine DOX concentration in the range of 1-100 
µg/mL. The conjugate between PC-1 or PC-2 with DOX were labeled as 








Scheme 4.1. (A) Synthesis of MTC-Bz, (B) polymerization of PC-1 from 
MTC-Bz and PEG 5k and (C) formation of DOX-1 via conjugation of PC-1 
and DOX-NH2. 
 
4.2.4. Preparation and characterization of micelles 
DOX-1 or DOX-2 (10 mg) was dissolved in 1 mL of DMSO, followed by the 
dropwise addition of this solution to 10 mL of PBS (pH 7.4) while being 
sonicated at 130 W by a probe-based sonicator (Vibra Cell VCX 130) for 2 
min. Then the solution was transferred to a centrifugal ultrafiltration tube with 
MWCO of 5 kDa and centrifuged at 4000 rpm for 30 min. Ultrafiltration was 
repeated 7-8 times by adding fresh PBS. Concentrated micelle solution was 
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filtered by 0.45 µm filter to remove large particles and stored in 4 °C for 
future use [214]. The size and zeta potential of DOX-loaded micelles in PBS 
(pH 7.4) were analyzed using Zetasizer 3000 HAS (Malvern Instrument Ltd., 
Malvern, UK) equipped with a He-Ne laser beam at 658 nm (scattering angle: 
90°). The concentration of the micelles was 100 mg/L. Each sample was 
measured 3 times and an average particle size and zeta potential was obtained. 
 
4.2.5. In vitro stability 
The stability of DOX-loaded micelles was evaluated by monitoring particle 
size change as a function of time at 100 mg/L in PBS (pH 7.4) at 4 °C and in 
RPMI 1640 cell culture medium containing 10% FBS and 1% 
penicillin-streptomycin at 37 °C. 
 
4.2.6. In vitro drug release 
The in vitro release experiments of DOX from the freshly prepared micelles 
were conducted in PBS at pH 5.0 and 7.4 at 37 °C. The DOX-loaded micelle 
solution was diluted by the corresponding buffer to 200 mg/L, and then put 
inside a membrane dialysis bag with MWCO of 2 kDa. The bag was immersed 
in 30 mL of the buffer while being shaken at 100 rpm. The solution outside the 
dialysis bag (1 mL) was collected at the predetermined time points and the 
same volume of fresh buffer was added. The DOX content in the solution was 
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determined using the UV-Vis spectrophotometer at 480 nm.  
 
4.2.7. Cellular uptake of DOX-loaded micelles 
The cellular uptake of DOX-loaded micelles was measured in MCF-7 and 
MCF-7/Adr cells by flow cytometry in comparison with free DOX. MCF-7 or 
MCF-7/Adr cells were seeded in a 24-well plate at a density of 5×104 
cells/well and incubated for 24 h. The medium was then replaced by fresh 
medium containing free DOX or DOX-loaded micelles (5 mg/L equivalent 
DOX concentration), and incubated for 2 h at 37 °C. After washed three times 
by cold PBS, the cells were trypsinized by incubation with 0.2 mL of 0.25% 
trypsin-EDTA solution for 2 min, and 1 mL of PBS was then added. The cells 
were collected by centrifugation at 800 rpm for 5 min, and re-suspended in 0.5 
mL of PBS. The extent of DOX uptake by the cells was determined on a 
Becton Dickinson FACSCalibur flow cytometer (BD Biosciences, U.S.A.) 
with the excitation and emission wavelengths of 532 and 595 nm respectively. 
The total number of events was recorded as 10,000. The data were analysized 
by using BD FACSDivat software (BD Biosciences, U.S.A.). 
 
4.2.8. Intracellular distribution 
The intracellular distribution of free DOX and DOX-loaded micelles was 
studied in both MCF-7 and MCF-7/Adr cells using the same method as 
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described under section 3.2.5.  
 
4.2.9. Cytotoxicity 
The in vitro cytotoxicity of blank micelles, free DOX and DOX-loaded 
micelles was investigated in MCF-7 and MCF-7/Adr cells by the MTT assay. 
Briefly, MCF-7 and MCF-7/Adr cells were seeded onto a 96-well plate at a 
density of 1×104 cells/well. The cells were incubated at 37 °C, 5% CO2 for 24 
h. After that, the used medium was replaced with 100 µL of fresh medium 
containing blank micelles, free DOX or DOX-loaded micelles at various 
concentrations. After 4 h of incubation, the medium was changed with fresh 
medium, and the cells were allowed to incubate for 48 h. At the end of the 
incubation, MTT assay was performed as described under section 3.2.7.  
 
4.2.10. Statistics 
All experiments were performed at least 3 times and presented as mean ± 
standard deviation (SD). The differences in study groups were evaluated using 
Student’s t-test, which were considered statistically significant if p<0.05, and 
highly significant if p< 0.01. 
 




4.3.1. Synthesis and characterization of monomer and polymers 
The functionalized aldehyde monomer MTC-Bz was prepared using a 
two-step synthetic approach. Firstly, 4-(3-hydroxypropoxy)benzaldehyde was 
formed via simple alkylation of 4-hydroxybenzaldehyde (Scheme 4.1A). 
MTC-Bz was then generated by the transesterification of activated esters. 
Byproducts from the transesterification reaction were removed using column 
chromatography.  
 
Polycarbonates-1 and 2 (PC-1 and PC-2) were prepared via organocatalytic 
ring-opening-polymerization of MTC-Bz. This approach employed a 
bifunctional co-catalyst system utilizing both DBU and a thiourea, yielding 
polymers of controlled molecular weight (Mn: PC-1 - 9.9 kDa, PC-2 - 14.6 
kDa) and narrow polydispersity (polydispersity index: PC-1 - 1.04 and PC-2 - 
1.04). Additionally, the use of organocatalysis permits complete catalyst 
removal, eliminating exogenous polymer toxicity. The block copolymer 
structure was created using monomethyl PEG (either 5 kDa or 8 kDa for PC-1 
and PC-2 respectively) as a biocompatible hydrophilic macroinitiator, 
followed by the addition of MTC-Bz (DP = 15) for providing the hydrophobic 
region for self-assembly while also installing the reactive aldehydes. The 
compositions of PC-1 and 2 were estimated from 1H NMR spectra by 
quantitative comparisons between integral intensities of the peaks of aldehyde 
protons (δ 9.85 ppm) and methylene groups of PEG (δ 3.50 ppm). There are 
95 
 
12 and 10 units of MTC-Bz in PC 1 and 2, respectively. 
 
4.3.2. Synthesis and characterization of DOX-polymer conjugates 
DOX and PC-1 or 2 were reacted in DMSO for 16 h, and DMSO and free 
DOX were then removed by dialysis against de-ionized (DI) water for 5 days. 
The chemical structure of DOX-polymer conjugates was characterized by 1H 
NMR and IR. The typical 1H NMR spectra of PC-2, DOX and DOX-2 
conjugates are shown in Fig. 4.1. The characteristic peaks of DOX and PC-2 
are all clearly observed in DOX-polymer conjugates. In particular, after 
conjugated with DOX, the peak of aldehyde groups significantly decreased 
and there were 5 free aldehyde groups left in each DOX-2 molecule (grafting 
ratio: 50 %), indicating successful conjugation of DOX to the polymers 
through the formation of Schiff-base between the amine group in DOX and the 
aldehyde group in the polymer. Similarly, in each DOX-1 molecule, there are 
also 5 DOX moieties (grafting ratio: 42 %). Partial conjugation of DOX to the 
polymers might be due to reversible nature of Schiff-base formation [215, 
216], the steric hindrance rendered by DOX and benzene ring next to aldehyde 
and hydrogen bonding between aldehyde groups. Schiff-base bond can be 
cleaved in aqueous solution [216]. Thus, in DOX-1 and DOX-2 conjugates, 
there existed free DOX molecules. For example, from the quantitative 
comparison between the integral intensities of the peaks of ethylene groups of 
PEG in PC-2 (δ 3.50 ppm) and the peaks of methyl protons of DOX and on the 
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PC-2 backbone (δ 1.15 ppm) (Fig. 4.1), 16.7 % DOX in DOX-2 were free 
DOX molecules. In addition, the IR spectra of DOX-1 and DOX-2 conjugates 
(Fig. 4.2) further proved that DOX was conjugated to the polymers due to the 
presence of C=N peak at 1682 cm-1.  
 
The DOX-polymer conjugates were also characterized by GPC. As shown in 
Fig. 4.3, the elution time of DOX-1 and DOX-2 was earlier than that of PC-1 
and PC-2 or shifted towards higher molecular weight, which demonstrated that 
DOX was conjugated to the polymers. From UV-Vis analysis, the DOX 
content in DOX-1 and DOX-2 was 35.4 wt % and 24.7 wt % respectively. 
 
4.3.3. Preparation and characterization of micelles 
DOX-1 and DOX-2 conjugates formed micelles with nanosize and narrow size 
distribution (Fig. 4.4), indicating that these micelles are desirable for tumor 
accumulation and biodistribution [94]. The zeta potential values of DOX-1 
and DOX-2 micelles in PBS (pH 7.4) were close to neutral (i.e. -1.7 ± 0.5 and 
-2.6 ± 0.9 mV respectively), which is ideal for in vivo systemic applications as 
neutral charged surface of nanoparticles can exhibit prolonged blood 
circulation and less uptake by phagocytic cells [93,187]. In addition, as shown 
in Fig. 4.5, the micelles were stable in both PBS and serum-supplemented 
RPMI-1640 growth medium up to 5 days, indicating that these micelles would 






Fig. 4.1. 1H NMR spectra of PC-2 (A), DOX (B) and DOX-2 (C). 
 
 










































































































































































Fig. 4.2. IR spectra of DOX-1 (A), DOX-2 (B) and free DOX (C). 
 
 












































































Micelles Size (nm) PDI Zeta-potential 
DOX-1 103±0.8 0.13 -1.68±0.50 
DOX-2 103±1.0 0.14 -2.65±0.91 
 
Fig. 4.4. Size distributions and zeta-potential of DOX-1 and DOX-2 micelles 





























































































Fig. 4.5. Stability of DOX-1 and DOX-2 micelles in PBS (pH 7.4) at 4 °C (A) 




4.3.4. In vitro drug release 
DOX release from the micelles was studied at pH 7.4 and 5.0 to simulate the 
extracellular and endolysosomal environments respectively [195,218]. DOX 
contents in DOX-1 and DOX-2 were determined from UV-Vis at 480 nm to be 
35.4 wt % and 24.7 wt %, respectively. As shown in Fig. 4.6, DOX release 
was indeed pH-sensitive, which was much faster at pH 5.0. For example, over 
48 h, DOX release from the DOX-1 and DOX-2 micelles at pH 5.0 was 56.6 ± 
0.4% and 50.9 ± 1.6% respectively, while only 23.7 ± 0.9% and 23.2 ± 0.7% 
DOX were released at pH 7.4. These results indicate that the micelles are 
stable in the blood circulation, but release DOX readily in the 
endosomes/lysosomes. The accelerated DOX release from the micelles at the 
lower pH was attributed to pH-sensitive Schiff-base linkage between DOX 
and the polymers. Slow DOX release at pH 7.4 was also reported in other 
studies on DOX-polymer conjugates through Schiff-base linkage [192,212], 
which might be due to the reversible nature of Schiff-base linkage and 
































































































Fig. 4.6. In vitro release of DOX from DOX-1 (A) and DOX-2 (B) micelles in 
PBS at pH 7.4 and pH 5.0 at 37 °C. 
 
4.3.5. Cellular uptake of DOX 
The cellular uptake of free DOX, DOX-1 and DOX-2 micelles was first 
investigated in MCF-7 and MCF-7/Adr cells qualitatively by confocal 
microscopy. In MCF-7 cells (Fig. 4.7A), the free DOX molecules were mainly 
distributed in the nucleus, whereas DOX-1 and DOX-2 micelles were found in 
both the nucleus and cytosol with majority being in the cytosol. In 
drug-resistant MCF-7/Adr cells (Fig. 4.7B), little fluorescence was observed in 
the cells incubated with free DOX, implying limited cellular uptake. In sharp 
contrast, DOX-1 and DOX-2 micelles were readily taken up by the cells 
although most micelles were seen in the cytosol at 2 h. Besides, the cellular 
uptake of free DOX, DOX-1 and DOX-2 micelles was also studied 
quantitatively by flow cytometry. In MCF-7 cells, the mean geometric 
fluorescence intensity (MGFI) of cells treated with free DOX was higher than 
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those of cells administered with DOX-1 and DOX-2 micelles (Fig. 4.8A), 
while for doxorubicin-resistant MCF-7/Adr cells, DOX-1 and DOX-2 micelles 
provided 2.9- and 3.9-fold higher MGFI than free DOX (Fig. 4.8B). This trend 
was in agreement with that of confocal imaging (Fig. 4.7). 
 
These cellular uptake results indicate that MDR transporter proteins such as 
P-gp in MCF-7/Adr cells impeded free DOX accumulation in MCF-7/Adr 
cells. DOX-1 and DOX-2 micelles were not subjected to drug efflux, which 
may be due to the fact that the micelles were taken up by the cells through 
non-specific endocytosis [219]. The intracellular drug distribution difference 
between free DOX and DOX-1/2 micelles in MCF-7 cells was probably 
because DOX release was sustained from the micelles and the micelles were 
too big to cross the nuclear membrane directly. This phenomenon was also 




















Fig. 4.7. Confocal images of MCF-7 cells (A) and MCF-7/Adr cells (B) after 



















Fig. 4.8. Cellular uptake of DOX by MCF-7 and MCF-7/Adr cells analyzed by 
flow cytometry. 
 
4.3.6. In vitro cytotoxicity 
As can be seen from the Fig. 4.9, the blank micelles had no cytotoxicity to 
MCF-7 and MCF-7/Adr cells up to 200 mg/L. For MCF-7 cells, free DOX had 
higher cytotoxicity as compared with the micelle formulations in the 
concentration range from 0.1 to10 µg/mL, which was due to slow release of 
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DOX [221]. In DOX-resistant MCF-7/Adr cells, both free DOX and micellar 
formulations were ineffective in suppressing cell proliferation at low 
concentrations. However, at 80 mg/L, DOX-1 and DOX-2 micelles were 
significantly more potent than free DOX. These results are in good agreement 
with the observations from confocal microscopy and flow cytometry studies, 
further demonstrating that DOX-1 and DOX-2 micelles prevented drug efflux 

























































































































































Fig. 4.9. Viability of MCF-7 (A, C) and MCF-7/Adr (B, D) cells after treated 




In this chapter, two amphiphilic diblock copolymers of PEG (Mn 5 and 8 kDa) 
and polycarbonate with aldehyde functional groups were successfully 
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synthesized via organocatalytic ROP of MTC-Bz using PEG as a 
macroinitiator. DOX was conjugated to the hydrophobic polycarbonate block 
via acid-labile Schiff-base linkage. The DOX-polymer conjugates formed 
nano-sized micelles in aqueous solution with narrow size distribution. The 
micelles were stable in the simulated physiological environment (PBS, pH 7.4) 
and serum-containing medium. DOX release from the micelles was 
pH-dependent, being faster in the acidic endolysosomal environment (pH 5.0) 
than in the extracellular environment (pH 7.4). In DOX-sensitive MCF-7 cells, 
the cellular uptake of free DOX was higher than that of micelles. 
DOX-resistant MCF-7/Adr cells did not take up free DOX, while 
DOX-conjugated micelles entered the cells readily, leading to greater efficacy 
in suppressing the cell proliferation. These biodegradable and pH-sensitive 
polycarbonate micelles with nano-size and narrow size distribution hold great 
promise as drug carrier for the delivery of anticancer drugs to overcome MDR 










Chapter 5 pH-sensitive polymeric micelles formed from boronic 





In chapter 4, pH-sensitive polymeric micelles formed by the conjugates 
between aldehyde-functionalized copolymers and DOX via Schiff-base bond 
have been developed. These micelles showed pH-sensitive drug release, and 
hold great potential in overcoming MDR in cancer treatment. As mentioned in 
chapter 1, pH-sensitive micelles systems could contain either acid-labile 
chemical bonds between drug molecules and polymers or pH-sensitive 
ionizable functional pendant groups in the polymer side chains. In this chapter, 
another pH-sensitive polymeric micelle system was designed and prepared 
using diblock copolymer of PEG and boronic acid-functionalized 
polycarbonate for the delivery of DOX into 3D tumorspheres. 
 
Boronic acid-functionalized macromolecules are a unique group of 
stimuli-responsive polymers widely used as pH-sensitive drug carriers 
[222-224]. The stimuli-responsive property of boronic acid-functionalized 
polymers mainly relies on the reversible boronate ester bond formed between 
boronic acid group and 1,2- or 1,3-diols or catechol group containing 
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molecules. For example, Aguirre-Chagala et al. designed and synthesized 
phenylboronic acid-functionalized polycarbonates for the delivery of a diol 
containing drug, capecitabine (CAPE). The conjugates of polymer and CAPE 
self-assembled into nanoparticles. Due to the boronate ether bond formed 
between the phenylboronic acid groups and diols, these nanoparticles showed 
pH-sensitive drug release [222]. In another example, phenylboronic 
acid-modified cholesterol was attached onto catechol-pending 
methoxypoly(ethylene glycol)-block-poly(L-lysine) via boronate ether bond to 
form amphiphilic diblock polymer. This polymer could self-assemble into 
micelles and DOX was successfully loaded into these micelles. Owing to the 
acid-cleavable boronate ether bond, the micellular structure would dissociate 
at pH 5, leading to the liberation of DOX. Additionally, they also found that 
using NH4Cl to block the lysoendosomal acidification in Hela cells could 
inhibit the intracellular DOX release and decrease the cytotoxicity of 
DOX-loaded micelles, indicating that the pH-sensitive DOX release from the 
micelles played a significant role in enhancing the anticancer efficacy of drug 
delivery system [223].  
 
In chapter 3, acid-functionalized and urea-functionalized diblock copolymers 
have been synthesized to prepare mixed micelles as carriers for the delivery of 
DOX. Owing to the ionic interactions and hydrogen bonding interactions 
between the carboxylic acid groups in polymers and the amine groups in DOX, 
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these micelles had high drug loading level. However, carboxylic acid based 
micellar system was not pH-sensitive due to the low pKa value of carboxylic 
acid group (~5), whereas the relatively higher pKa value of boronic acid group 
(~9) would be more advantageous in achieving pH-dependent drug release. 
Apart from its pH-sensitivity, another reason of choosing boronic acid based 
polymeric micellar drug delivery system was due to its expectant high drug 
loading capacity. We expected that the electrostatic and hydrogen bonding 
interactions between the boronic acid groups and DOX could equally yield 
satisfactory drug loading level to achieve promising antitumor therapeutic 
effects. 
  
In drug delivery research, cells in two dimensional (2D) monolayer formed in 
multi-well plates are the most widely used in vitro cell model for testing the 
effects of free drugs or drug-loaded nanoparticles. However, results gathered 
from experiments performed on the 2D monolayer cells are sometimes 
inconsistent with those gathered from in vivo studies. This was due to the fact 
that 2D monolayer cells lack cell-cell interactions as well as extra-cellular 
matrix (ECM), which are important barriers in in vivo drug delivery [225,226]. 
Thus, three dimensional (3D) tumorspheres have been developed as a new and 
more desirable drug testing platform in vitro. Compared with the conventional 
2D monolayer cells, 3D tumorspheres are more close to in vivo 3D tumor 
structures, which are characterized by complex cell and cell interactions, ECM, 
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hypoxia region and low-pH microenvironments [226].  
 
Inspired by the idea of using boronic acid-based high loading and pH-sensitive 
drug delivery system performed on a 3D tumorsphrere model, in this chapter, 
we designed and synthesized diblock copolymer of 10 kDa PEG and boronic 
acid-functionalized polycarbonate (PEG-PBC) using 
ring-opening-polymerization in our lab by David Voo in IBN. The boronic 
acid groups in this polymer were expected to help achieve high DOX loading 
by forming strong ionic interactions and hydrogen bonding interactions with 
DOX, as well as to form pH-sensitive micelles for the delivery of DOX into 
3D tumorspheres. In order to enhance the stability of the micelles, diblock 
copolymer of 10 kDa PEG and urea-functionalized polycarbonate (PEG-PUC) 
was used to mix with PEG-PBC to form mixed micelles. Due to the hydrogen 
bonding interactions between urea groups and boronic acid groups, the mixed 
micelles were expected to be more stable than the single polymer micelles 
based on PEG-PBC. After preparation using thin-film hydration method, the 
particle size, size distribution, zeta potential and drug encapsulation efficiency 
of drug-loaded micelles were determined and the drug release was assessed at 
both pH 7.4 and pH 5.0. The stabilities of these micelles in serum containing 
PBS and in the presence of SDS were also investigated. Moreover, the cellular 
uptakes, cellular distribution and cytotoxicity of DOX-loaded micelles were 
assessed on BT-474 2D monolayer cells and compare with free DOX. Finally, 
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BT-474 3D tumorspheres model was established, and the penetration ability, 
cellular uptake, tumor inhibition efficiency and live/dead assay of 
DOX-loaded micelles were studied and compared with free DOX. 
 
5.2. Materials and Methods 
 
5.2.1. Materials 
Doxorubicin-hydrochloride (DOX-HCl) and Hoechst 33342 and all other 
reagents were purchased from Sigma-Aldrich (St. Louis, MO, U.S.A.) unless 
otherwise specified.  PEG (Mn 10 kDa, PDI 1.10) was purchased from 
Polymer SourceTM, lyophilized and transferred to a glove-box one day prior 
to use. 1,8-Diazabicyclo[5,4,0]undec-7-ene (DBU) was dried over CaH2 
overnight, and dried DBU was obtained after vacuum distillation. DBU were 
transferred to a glove-box prior to use. Human breast cancer cell lines BT-474 
was purchased from ATCC (Manassas, VA, U.S.A.). Cells were cultured in 
RPMI-1640 medium (Lonza, Singapore) supplemented with 10% fetal bovine 
serum (FBS), 100 U/mL penicillin and 100 U/mL streptomycin at 37 °C in 5% 
CO2 atmosphere. 
 
5.2.2. Synthesis and characterization of monomers and diblock copolymers  
Diblock copolymer of PEG and boronic acid-functionalized polycarbonate 
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(PEG-PBC) was synthesized by David Voo in IBN (Scheme 5.1). Diblock 
copolymer of PEG and urea-functionalized polycarbonate (PEG-PUC) was 
synthesized by Dr. Victor Ng in IBN. The polymers were synthesized via 
metal-free organocatalytic ring-opening-polymerization of functionalized 
MTC using mPEG as macroinitiator. The details of the synthesis and 
characterization of PEG-PBC are provided in Appendix 3, and the details of 
the synthesis and characterization of PEG-PUC are provided in Appendix 1. 
 
 
Scheme 5.1. Synthesis of diblock copolymer of PEG and boronic 
acid-functionalized polycarbonate. 
 
5.2.3. Determination of critical micelle concentration (CMC) 
The CMC values of the PEG-PBC, PEG-PUC and the mixture of PEG-PBC 
and PEG-PUC were measured in deionized (DI) water by a LS50B 
luminescence spectrometer (Perkin Elmer, U.S.A) using pyrene as probe.  
Briefly, pyrene in acetone solution (10 μL, 6.16 × 10-5 M) was added into 
glass vials. After the acetone was evaporated, polymer solution (1 mL) with 
various concentrations ranging from 0.01 to 2000 mg/L was added into each 
vial and mixed with pyrene by votexing. After incubation overnight, the 
solutions were scanned from 300 to 360 nm with an emission wavelength of 
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395 nm to get the excitation spectra. Both excitation and emission bandwidths 
were set at 2.5 nm. The intensity ratios of I337/I334 obtained from the 
excitation spectra were used to plot a curve as a function of polymer 
concentration. The intersection of the tangent to the curve at the inflection and 
the tangent of the points at low polymer concentrations gave the CMC value. 
 
5.2.4. Preparation and characterization of micelles 
DOX-loaded micelles formed from PEG-PBC (DOX/B micelles) and 
DOX-loaded mixed micelles formed from PEG-PBC/PEG-PUC (DOX/B+U 
mixed micelles) were prepared using thin-film hydration method as described 
in the literature with minor modification [227]. Briefly, 5 mg DOX-HCl was 
dissolved in 1 mL of methanol containing three mole equivalents of 
triethylamine (3.84 µL).To this solution was added PEG-PBC (10 mg) or a 
mixture of PEG-PBC (4.8 mg) and PEG-PUC (5.2 mg) (molar ratio of boronic 
acid group and urea group was 1:1) dissolved in 1 mL of methanol. The mixed 
solution was transferred into round bottom flask and the organic solvent was 
removed using rotary evaporator at 50 °C for 30 min to form thin-film. The 
hydration was performed by adding 5 ml PBS into the round bottom flask and 
followed by sonicating at 50 °C for 30 min to form micelles. Free DOX was 
then removed by filtering the solution through 0.22 µm filter.  
 
The particle size and size distribution of the micelles was determined using a 
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DTS Zetasizer Nano (Malvern Instruments, Worcestershire, UK). The drug 
encapsulation efficiency of the micelles was quantified using UV-Vis 
spectrophotometer (UV 2501PC Shimadzu, Japan). The drug encapsulation 
efficiency was then calculated using the following formula: encapsulation 
efficiency % = (mass of drug loaded in micelles/mass of initial loading drug) × 
100%. 
 
The stability of DOX-loaded micelles was evaluated by monitoring particle 
size change as a function of time at 100 mg/L in PBS (pH 7.4) containing 
10 % FBS at 37 °C. The kinetic stability of DOX-loaded micelles was 
evaluated by monitoring relative scattered light intensity change as a function 
of time in the presence of sodium dodecyl sulfate (SDS, 2.23 mg/mL) acting 
as a destabilizing agent at room temperature. 
 
5.2.5. In vitro drug release 
The in vitro drug releases of the two types of DOX-loaded micelles were 
studied at both pH 7.4 and pH 5.0 PBS. The method is the same as described 
under section 3.2.4. 
 
5.2.6. Intracellular distribution 
The intracellular distribution of free DOX and the two types of DOX-loaded 
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micelles was studied on BT-474 cells using the same method as described 
under section 3.2.5.  
 
5.2.7. Cellular uptakes 
The cellular uptakes of free DOX and the two types of DOX-loaded micelles 
were measured on BT-474 cells using the same method as described under 
section 4.2.5. 
 
5.2.8. In vitro cytotoxicity 
The in vitro cytotoxicyt assay of free DOX and the two types of DOX-loaded 
micelles was measured on BT-474 cells using the same method as described 
under section 3.2.7 and 3.2.10. 
 
5.2.9. Establish 3D tumorspheres  
The 3D tumorspheres were established using non-adherent surfaces method 
[226]. Agarose solution (2%, w/v) was dissolved in PBS at 80 °C and then 
sterilized under autoclave. 70 µL of the sterilized agarose solution was then 
added to each well of the 96-wells plate and incubated at room temperature for 
30 min. Cell suspension solution in cell culture medium (1000 cells in 100 µL) 
was added into each well followed by centrifugetion at 1000 rpm for 5 min. 
The cells formed aggregation at the center of each well and it took 4 days for 
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them to grow into tumorspheres. 
 
5.2.10. Penetration abilities of various formulations on tumorspheres 
To compare the penetration abilities of the two types of DOX-loaded micelles 
and free DOX, tumorspheres were incubated with free DOX, DOX/B micelles 
and DOX/B+U mixed micelles at the concentration of 10 µM for 24 h. After 
washing with PBS, the tumorspheres were scanned using a confocal laser 
scanning microscope (CLSM, Olympus FV300, Japan) using z-stack with 
each layer of 10 µm. 
 
5.2.11. Cellular uptake on tumorspheres 
The cellular uptake of various formulations by the tumorspheres was studied 
using flow cytometry. Tumorspheres were incubated with free DOX, DOX/B 
micelles and DOX/B+U mixed micelles at the concentration of 10 µM for 24 h. 
After washing with PBS, the tumorspheres were trypsinized by incubation 
with 0.2 mL of 0.25% trypsin-EDTA solution for 2 min, and 1 mL of PBS was 
then added. The cells were collected by centrifugation at 1000 rpm for 5 min, 
and re-suspended in 0.5 mL of PBS. The extent of DOX uptake by the cells 
was determined on a Becton Dickinson FACSCalibur flow cytometer (BD 
Biosciences, U.S.A.) with the excitation and emission wavelengths of 532 and 
595 nm respectively. The total number of events was recorded as 10,000. The 
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data were analysized by using BD FACSDivat software (BD Biosciences, 
U.S.A.). 
 
5.2.12. Inhibition effects on tumorspheres 
To understand the inhibition effects of various formulations, tumorspheres 
were treated with free DOX, DOX/B micelles and DOX/B+U mixed micelles 
at the concentration of 10 µM, respectively. The morphology changes of the 
tumorspheres under different treatment conditions were recorded at day 0, 3, 7, 
14 and 21 under microscopy (Leica DMI6000 B). 
 
5.2.13. Live/dead assay on tumorspheres 
To further evaluate the inhibition effects of various formulations on 
tumorspheres, a Cell Viability Imaging Kit, Blue/Green (R37609, Life 
Technologies) was used to detect the live/dead cells in tumorspheres. In this 
assay, NucGreen® Dead reagent that only stains the nuclei of cells with 
compromised plasma membrane integrity, was used to label dead cells; while 
NucBlue® Live reagent (Hoechst 33342) that stains the nuclei of all the cells, 
was used to label both live and dead cells. The tumorspheres were treated with 
free DOX, DOX/B micelles and DOX/B+U mixed micelles at the 
concentration of 10 µM, respectively. At day 0 and 3, the tumorspheres were 
stained with the kit according to the manufacturer’s instructions, and then 
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All experiments were performed at least 3 times and presented as mean ± 
standard deviation (SD). The differences in study groups were evaluated using 
Student’s t-test, which were considered statistically significant if p<0.05, and 
highly significant if p< 0.01. 
 
5.3. Results and discussion 
 
5.3.1. Synthesis of boronic acid functionalized monomer and doblock 
copolymer 
The synthesis of boronic acid functionalized monomer (MTC-PPB) was a 
straightforward reaction which involved the direct coupling of MTC-Cl with 
4-hydroxymethyl phenylboronic acid pinacol in the presence of triethylamine, 
with a yield of 52 % after column and recrystallization, which allowed 
subsequent successful polymer synthesis. The polymers were synthesized via 
metal-free organocatalytic ROP of MTC-PPB using mPEG of 10 kDa as a 
macroinitiator in the presence of the co-catalysts DBU (Fig 5.1a) for 3.5 hours. 
The reaction was quenched with benzoic acid and left to stir for 5 min. 1H 
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NMR integration values of monomers relative to the PEG initiator correlated 
well, confirming controlled polymerization and predictable molecular weights 
via initial monomer to initiator feed ratio. In addition, the proton NMR 
analysis displayed all the peaks associated with both initiator and monomers 
(Fig. 5.1a). From the GPC result, the polymer had narrow molecular weight 
distribution with PDI 1.16. Subsequently, after precipitating twice in cold 
diethyl ether, the polymers were isolated and dried. The pinacol protected 
phenylboronic acid groups in the polymers were subsequently deprotected by 
dissolving in 1:1 THF/methanol solvent and heated to 50 °C overnight with 
benzene 1,4 diboronic acid and acidic resins. The deprotected polymers were 
purified by re-precipitation in cold diethyl ether twice, and 1H NMR showed 
the disappearance of the methyl protons from the pinacol protecting groups. In 
addition, the presence of a new distinct peak at 8.05 ppm confirmed the 
presence of hydroxyl groups which correlates to the deprotected 
phenylboronic acid pendant groups (Fig. 5.1b). The deprotected polymers 








Fig. 5.1. 1H NMR spectra of (a) pinocal protected PEG-PBC and (b) 
PEG-PBC. 
 
5.3.2. Characterization of drug-loaded micelles 
The particle size of DOX/B micelles and DOX/B+U mixed micelles were 72 
± 1 nm and 67 ± 1 nm, respectively. Both micelles had a narrow size 
distribution (PDI: 0.19 ± 0.03 for DOX/B micelles and 0.15 ± 0.01 for 
DOX/B+U mixed micelles). These results indicated that these micelles are 
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desirable for tumor accumulation and biodistribution [94]. The zeta potential 
values of DOX/B micelles and DOX/B+U mixed micelles in PBS (pH 7.4) 
were close to neutral (i.e. -0.8 ± 1.4 and -1.1 ± 1.1 mV respectively), which is 
ideal for in vivo systemic applications as neutral charged surface of 
nanoparticles can exhibit prolonged blood circulation and less uptake by 
phagocytic cells [187]. Both PEG-PBC and the mixture of PEG-PBC and 
PEG-PUC had low CMC values. However, compared to PEG-PBC polymer, 
the mixture of PEG-PBC and PEG-PUC had a lower CMC value (4.3 mg/L vs. 
8.0 mg/L), indicating that the mixed micelles had enhanced thermodynamic 
stability compared to the single polymer micelles, probably due to the strong 
hydrogen bonding interactions between the boronic acid groups and urea 
groups in these two polymers. In addition, as shown in Fig. 5.2, both micelles 
were stable in serum-supplemented PBS up to 24 h, indicating that these 
micelles would not be prone to dissociation and aggregation in the 
physiological environment [228]. Furthermore, the kinetic stability of the two 
micelles was measured in the presence of SDS. Form Fig. 5.3, it can be seen 
that, DOX/B+U mixed micelles showed much higher kinetic stability than 
DOX/B micelles. At 48 h, the relative intensity of DOX/B+U mixed micelles 
was much higher compared to that of DOX/B micelles (66 % vs. 10 %). This 
enhanced kinetic stability of DOX/B+U mixed micelles indicated that they 





















Fig. 5.2. Stability of DOX/B micelles and DOX/B+U mixed micelles in 10% 































Fig. 5.3. Kinetic stability of DOX/B micelles and DOX/B+U mixed micelles 
in the presence of SDS. 
 
5.3.3. In vitro drug release 
DOX release from the two micelles was studied at pH 7.4 and 5.0 to simulate 
the extracellular and endolysosomal environments respectively [229]. As 
shown in Fig. 5.4, DOX release from both micelles was indeed pH-sensitive, 
which was much faster at pH 5.0 than that at pH 7.4. For example, over 24 h, 
DOX release from the DOX/B micelles and DOX/B+U mixed micelles at pH 
5.0 was 77.3 ± 4 % and 66.1 ± 4.6 % respectively, while only 37.1 ± 2.7 % and 
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28.2 ± 1.5 % DOX were released at pH 7.4. These results indicated that the 
micelles would be stable in the blood circulation, but would release DOX 
readily in endosomes/lysosomes in cancer cells. The accelerated DOX release 
from the micelles at lower pH was attributed to the acid mediated disruption of 
the ionic interactions between the amine groups of DOX and the borinic acid 
groups of polymer. Compared to DOX/B+U mixed micelles, DOX/B micelles 
showed slightly faster DOX release at both pH 5.0 and 7.4, due to the 
hydrogen bonding interactions between boronic acid groups and urea groups, 
which made the DOX/B+U mixed micelles form a more compact micellular 























Fig. 5.4. In vitro release of DOX from DOX/B micelles and DOX/B+U mixed 
micelles in PBS at pH 7.4 and pH 5.0 at 37 °C. 
 
5.3.4. Cellular uptake 
The cellular uptake of free DOX, DOX/B micelles and DOX/B+U mixed 
micelles was first investigated in BT-474 cells qualitatively by confocal 
microscopy. As can be seen in Fig. 5.5, after incubation with the cells for 2 h, 
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the free DOX molecules mainly accumulated in the nuclei, whereas DOX/B 
micelles and DOX/B+U mixed micelles were found in both the nuclei and 
cytosol. These results indicated that DOX could be timed released from both 
micelle formulations in cancer cells and enter into the nuclei. This timely drug 
release of the two micelles in cancer cells attributed to the pH-sensitive drug 
release in endosomes/lysosomes. 
 
Besides, the cellular uptake of free DOX, DOX/B micelles and DOX/B+U 
mixed micelles was also studied quantitatively by flow cytometry. As shown 
in Fig. 5.6, the mean geometric fluorescence intensity (MGFI) of cells treated 
with DOX/B+U mixed micelles and DOX/B micelles was significantly higher 
than that of cells administered with free DOX, which was consistent with 
other studies reported in the literature [230]. And the cells treated with 
DOX/B+U mixed micelles showed higher MGFI than the cells treated with 
DOX/B micelles, which might be due to the enhanced stability of DOX/B+U 





Fig. 5.5. Confocal images of BT-474 cells after treated with free DOX, 
DOX/B micelles and DOX/B+U mixed micelles. Blue: hoechst; green: 



















Fig. 5.6. Cellular uptake of DOX by BT-474 cells analyzed by flow cytometry. 
* p<0.05 vs. free DOX; ** p<0.01 vs. free DOX or DOX/B micelles. 
 
5.3.5. Cytotoxicity 
As can be seen from Fig. 5.7, in BT-474 cells, the DOX/B+U mixed micelles 
showed the strongest anticancer activity, and the DOX/B micelles showed 
stronger anticancer activity than free DOX. These results were consistent with 
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the cellular uptake results (Fig. 5.6). The blank micelles showed no 
cytotoxicity on BT474 cells up to 400 mg/L (Fig. 5.8), indicating that the 









































Fig. 5.7. Viability of BT-474 cells after treated with free DOX, DOX/B 
micelles and DOX/B+U mixed micelles for 48 h. 1, p<0.01, vs. free DOX or 


























Fig. 5.8. Viability of BT-474 cells after treated with blank micelles for 48 h. 
 
5.3.6. Penetration abilities on BT-474 tumorspheres 
The penetration abilities of various formulations on BT-474 tumorspheres 
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were firstly investigated qualitatively by confocal microscopy. As shown in 
Fig. 5.9, both DOX-loaded micelles penetrated much deeper than free DOX 
(penetration depth: 30-40 µm for the two micelles vs. 10-20 µm for free DOX). 
Besides, the penetration abilities were also studied quantitatively using flow 
cytometry. Both DOX-loaded micelles showed much higher cellular uptake 
than free DOX (Fig. 5.10), which was consistent with the confocal results (Fig 
5.9). The enhanced penetration abilities in tumorspheres of DOX-loaded 
micelles compared with free DOX were attributed to the PEG molecules in the 
micelle shells which could prevent the non-specific interactions with proteins 
and extracellular matrix (ECM). 
 
 
Fig. 5.9. Confocal images of BT-474 tumorspheres after treated with free 
DOX, DOX/B micelles or DOX/B+U mixed micelles for 24 h. Tumorspheres 

































Fig. 5.10. Cellular uptake of DOX by BT-474 tumorspheres after treated with 
free DOX, DOX/B micelles or DOX/B+U mixed micelles for 24 h. * p<0.05 
vs. free DOX. 
 
5.3.7. Inhibition effects on BT-474 tumorspheres 
In order to investigate the inhibition effects of various formulations on BT-474 
tumorspheres, the morphology changes of tumorspheres were monitored using 
microscopy. As can be seen in Fig. 5.11, the tumorspheres in the treatment 
groups of free DOX, DOX/B micelles and DOX/B+U mixed micelles started 
to dissociate at day 3. And this phenomenon became more obvious as a 
function of time. Correspondingly, the volumes of the tumorspheres in these 
three groups were deceasing over time. In sharp contrast, the tumorspheres 
treated with medium or blank micelles kept smooth surfaces and compact 
structures during the whole experimental period. And the volumes of these 
tumorspheres were increasing as a function of time. These results 
demonstrated that free DOX, DOX/B micelles and DOX/B+U mixed micelles 
could effectively inhibit the growth and cause the dissociation of tumorspheres. 
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To further confirm the inhibitory effects of various DOX formulations, 
live/dead assay was performed. As shown in Fig. 5.12, tumorspheres in all the 
groups consisted of live cells on day 0. After treatment with free DOX, 
DOX/B micelles or DOX/B+U mixed micelles for 3 days, there were a lot of 
dead cells in the tumorspheres. In contrast, the cells in the tumorspheres 
treated with medium were still alive. These results further demonstrated the 




Fig. 5.11. Morphology changes of BT-474 tumorspheres after being treated 
with medium, B blank micelles, B+U blank micelles, DOX/B micelles and 





Fig. 5.12. Live/dead assay of BT-474 tumorspheres after being treated with 
medium, free DOX, DOX/B micelles or DOX/B+U mixed micelles for 0 day 




In this chapter, pH-sensitive DOX-loaded polymeric micelles self-assembled 
from diblock copolymer of PEG and boronic acid-functionalized 
polycarbonate have been successfully developed. In order to enhance the 
stability, urea-functionalized copolymer was used to mix with boronic 
acid-functionalized copolymer to form mixed micelles. Both DOX/B micelles 
and DOX/B+U mixed micelles had nanosize with narrow size distribution and 
were stable in serum containing PBS over 24 h, they also both showed 
pH-sensitive drug release in vitro and timely drug release in BT-474 cells. 
Moreover, the DOX/B+U mixed micelles showed enhanced thermodynamic 
stability and kinetic stability compared with DOX/B micelles, as well as 
higher cellular uptakes than free DOX and DOX/B micelles, resulting in 
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stronger anticancer activity. Furthermore, free DOX, DOX/B micelles and 
DOX/B+U micelles showed inhibitory effects on BT-474 tumorspheres. 
However, DOX/B micelles and DOX/B+U mixed micelles could penetrate 
deeper in BT-474 tumorspheres than the free DOX. These pH-sensitive 
micelles hold great potential in the delivery DOX into solid tumors for cancer 
treatment. In the future, the systemic toxicity and antitumor efficiency of these 
two types of pH-sensitive DOX-loaded micelles could be further studied on 














Chapter 6 Hydrophilic polycarbonates: promising degradable 




As mentioned in chapter1, PEG, which is synthesized from the 
ring-opening-polymerization of ethylene oxide, is the gold standard 
shell-forming block for the preparation of polymeric micelles to provide 
stealth property. In general, it can be polymerized at a wide variety of 
molecular weights with a narrow dispersity. It is soluble in a wide range of 
organic and aqueous solvents. Furthermore, reactive functionalities at the 
polymer end groups can be introduced with ease, making it an excellent 
candidate for functionalization onto biologically relevant molecules. When 
PEG is in the bloodstream, water molecules form a neutral coating around the 
PEG, reducing adsorption of opsonins to the polymer surface and interaction 
of the polymer with the physiological environment [148,231,232]. PEGylated 
drugs and drug carriers have reduced enzymatic degradation, decreased uptake 
by the reticular endothelial system, and reduced renal filtration, resulting in 
increased circulation half-life and bioavailability [233]. Attaching PEG to 
therapeutics also significantly reduces toxicity of drugs and nanocarriers by 




PEGylated products have been on the market for 20 years, and there is a vast 
amount of clinical experience with this class of polymers [145]. Despite the 
many advantages conferred by PEG, there also remain several drawbacks to its 
usage. The most obvious disadvantage of PEG is that it is not biodegradable, 
and at high molecular weights, it can accumulate in tissue. For example, PEGs 
with molecular-weights below 40−60 kDa are required to prevent 
accumulation in the liver. Unfortunately, 40 kDa molecular weight PEG is 
commonly used for PEGylation of biologically active molecules [145]. In 
some patients, PEG can cause an immunological response and hypersensitivity 
as well as an accelerated blood clearance upon repeated exposure. Antibodies 
produced in response to PEG exposure have also been reported [148]. 
 
The aforementioned disadvantages associated with PEG have motivated 
researchers to develop alternative polymers for therapeutic delivery, a topic 
which has been the subject of several review articles [145,148]. Although 
significant research has been performed in this area, there are few synthetic 
biodegradable polymer alternatives that offer the same stealth properties and 
can be prepared with the same level of synthetic control as PEG. One strategy 
is to synthesize polymers containing short PEG units within the polymer 
backbone, connected through a degradable linkage [157,158,234,235] or PEG 
units attached to the side chain of a polymer with degradable backbone 
[144,159,236,237]. Although both systems are degradable, undesirable toxicity 
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can result if the PEG units have molecular weights lower than 400 Da 
[145,238]. Polycarbonates have the potential to be both water-soluble and 
biodegradable [239,240]. Recently, Chan et al. reported zwitterionic 
polycarbonates prepared by a well-controlled ring-opening polymerization. 
These polymers exhibited both degradability and nonfouling characteristics 
[241]. One common issue with zwitterionic polymers is that they exhibit 
minimal solubility in most organic solvents, thereby requiring subsequent 
synthetic transformations to be performed in aqueous media, which presents 
challenges if conjugation to a hydrophobic drug molecule is desired. Others 
have reported on hydroxylcontaining polycarbonates prepared from epoxides 
and CO2 using a metal catalyst [242,243]. Poly(amino acid)-based polymers, 
such as poly(hydroxyethyl-L-asparagine) and 
poly-(hydroxyethyl-L-glutamine), that have side groups containing hydroxyl 
groups attached through an amide linkage also show PEG-like characteristics 
(Fig. 6.1) [155,244]. These materials are prepared by the 
ring-opening-polymerization of N-carboxyanhydrides and degrade 
enzymatically in vivo into their corresponding amino acids [241,242]. A 
similar non-biodegradable methacrylate-based polymer, 
poly(N-(2-hydroxypropyl)-methacrylamide) (Fig. 6.1), reported by Duncan 
and others, has been evaluated in clinical trials with promising results 
[145,164]. In both of these polymer systems, the OH groups enhance water 
solubility and the amide groups facilitate hydrogen bonding with water 
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molecules [245]. These polymers are also soluble in both aqueous and select 
organic solvents. 
 
Fig. 6.1. Polymers containing hydroxyl side groups attached through an amide 
linkage. 
 
Therefore, in this chapter, to synthesize PEG alternatives, we have designed 
and synthesized a series of hydrophilic polycarbonates containing hydroxyl 
groups attached to the polymer side chain via an amide linkage. These 
materials have many of the positive characteristics of PEG including, access to 
a wide range of molecular weights, a narrow dispersity, solubility in both 
water and organic solvents, and minimal toxicity. Unlike PEG and the above 
mentioned polymers containing amide-linked alcohol side groups, 
polycarbonates are both hydrolytically and enzymatically degradable [239,240] 
These new water-soluble polycarbonates are prepared by metal-free, 
acid-catalyzed ring-opening-polymerization of a cyclic carbonate monomer 
containing an activated ester (MTC-OC6F5) [246]. After polymerization, the 
activated ester polymer was functionalized with various amino alcohols, 
yielding a series of polycarbonates with pendent alcohol side chains attached 
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by an amide linkage (Scheme 6.1). The pendant OH groups facilitate polymer 
side-chain hydration, and the resulting amide linkage was added to promote 
hydrogen bonding of the water molecules. The polymers were characterized 
by gel permeation chromatography (GPC) and 1H NMR spectroscopy to verify 
that the introduction of the desired OH group had no detrimental effects on the 
selectivity of the amines over hydroxyls. Polymer toxicity was determined 
using cell viability and LD50 studies. Nonfouling characteristics were 
determined using aggregation studies, in which polymers were shown to resist 
nonspecific protein interactions. Furthermore, diblock copolymers were also 
synthesized to determine if these polymers could be utilized as micellar drug 
delivery systems. 
 
Scheme 6.1. Synthesis of water-soluble polycarbonates. 
 





MTC-OC6F5 was obtained from Central Glass and purified by crystallizing 
twice from a mixture of ethyl acetate and hexanes. MTC-OEt was prepared 
according to literature protocol [247].  Dichloromethane was dried using 
activated alumina columns and stored over molecular sieves (3 Å). All other 
materials were purchased from Sigma-Aldrich and used as received. Human 
embryonic kidney cell line HEK293 purchased from ATCC (Manassas, VA, 
U.S.A.). Cells were cultured in RPMI-1640 medium (Lonza, Singapore) 
supplemented with 10 % fetal bovine serum (FBS), 100 U/mL penicillin and 
100 U/mL streptomycin at 37 °C in 5 % CO2 atmosphere. 
 
6.2.2. Synthesis and characterization of homopolymers and copolymers 
The biodegradable hydrophilic polycarbonate polymers were synthesized by 
our collaborator Dr. Amanda C. Engler in IBM Almaden Research Center. The 
polymers were synthesized via metal-free organocatalytic 
ring-opening-polymerization of functionalized methylcarboxytrimethylene 
carbonate (MTC). The details of the syntheses and molecular characterization 
are provided in Appendix 4. 
 
6.2.3. Cytotoxicity 
The in vitro cytotoxicity assay of various polymers was measured on HEK293 
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cells using the same method as described under section 3.2.7 and 3.2.10. 
 
6.2.4. LD50 studies 
Female BALB/c mice (19−21 g) were randomly selected and kept in cages for 
at least 5 days to allow for acclimatization to the laboratory conditions. Before 
injection, mice were fasted for 12 h before testing. Polymer was dissolved in 
sterilized saline solution at a concentration of 50 mg/mL and administered via 
intravenous (i.v.) injection at a dose of 500 mg/kg. Polymer solution was 
initially given to one mouse, and if the first mouse survived after 48 h, two 
more mice were further used for the test. After injection, all the animals were 
observed every 30 min for the first 4 h and daily thereafter, for a total of 14 
days. 
 
6.2.5. Aggregation study 
Polymers were dissolved in PBS containing 10 % FBS. The particle sizes 
within the polymer solutions were analyzed using a Zetasizer 3000 HAS 
(Malvern Instrument Ltd., Malvern, UK) equipped with a He−Ne laser beam 
at 658 nm (scattering angle: 90°) over 24 or 48 h. The concentration of the 
polymers was 500 mg/L. Each sample was measured three times, and an 




6.3. Results and Discussions 
 
6.3.1. Synthesis and characterization of water-soluble polymers 
The polymers described in this work (Scheme 6.1) are based on an aliphatic 
polycarbonate backbone and were designed to be degradable analogues of 
poly(N-(2-hydroxypropyl)methacrylamide. Briefly, poly(MTC-OC6F5) was 
prepared via triflic acid-catalyzed ring-opening-polymerization of 
MTC-OC6F5 (degree of polymerization = 20, from GPC with THF as eluent: 
Mn = 6200 Da, PDI = 1.15). After polymerization, the polymers were 
functionalized with amino alcohols such that each repeat unit contains an 
amide and one or more hydroxyl groups. Complete functionalization was 
observed with the amine selectively reacting with the activated ester instead of 
reacting with the hydroxyl, ensuring that there was no deleterious 
cross-linking or ester formation. This chemoselectivity was also verified by 1H 
NMR and is shown in Fig. 6.2, which contains 1H NMR spectra of 
poly(MTC-OC6F5) and 3-aminopropanol postfunctionalization product (A-2). 
Quantitative reaction of the activated ester to an amide was verified by 
monitoring the shift in the polycarbonate backbone peaks (Fig. 6.2, a and b to 
a’ and b’, respectively) and the appearance of new peaks associated with small 
molecule amine substitution. Furthermore, integration of the new signals 
against that of the polymer backbone was consistent with complete 






Fig. 6.2. 1H NMR in CDCl3 of poly(MTC-OC6F5) and 
1H NMR in D2O of 
polymer A-2. R = Phenyl. 
 
During post polymerization modification, degradation of the polymer 
backbone was a concern because of the basic condition required for the 
functionalization reaction and the abundance of free hydroxyl groups. The 
polymers were analyzed by GPC to determine if there was a significant drop 
in molecular weight or broadening in dispersity. As summarized in Table 6.1, 
no broadening in dispersity was observed, and in all cases similar molecular 




Table 6.1. Summary of functionalized homopolymers including molecular 




6.3.2. Polymer stability 
One method of determining if a polymer system exhibit stealth characteristics 
is to look at polymer aggregation in serum. Using dynamic light scattering, the 
size of particles in serum can be measured. If the particle size remains 
consistent over time (i.e., the polymers are not causing aggregation), it 
indicates that the polymer is sufficiently hydrated such that it has nonfouling 
characteristics [248,249]. For these measurements, the water solubility of each 
of the new polymers was determined by placing purified polymer (50 mg) in a 
small vial and adding water (1 mL). If the solution was clear at a concentration 
of 50 mg/mL, the polymer was labeled as water-soluble (Table 6.1). 
Poly(MTC-OC6F5) substituted with 2-aminobutanol did not visually dissolve 
(A-4), but all other polymers were fully water-soluble. The fully water-soluble 
polymers were then dissolved in PBS containing 10% FBS at a concentration 
of 500 mg/L. Particle size was measured as a function of time using dynamic 
light scattering, with PEG (2 kDa) used for comparison. For all water-soluble 
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polymers, the particle size remained constant over 24 h, indicating that there is 


























Fig. 6.3. Particle size measured by DLS as a function of time for 
homopolymers dissolved in 10% serum. 
 
6.3.3. Polymer toxicity 
Cell viability studies were performed using HEK293 cells. PEG (5 and 10 kDa) 
were used as controls. As shown in Figure 6.4, only the polymer substituted 
with 2-amino-1-butanol exhibited cell viability that drops below 80%. This 
toxicity is most likely a result of the high hydrophobicity associated with this 
polymer. All other polymers show similar toxicity profiles to what is observed 
for the 5 and 10 kDa PEG. The more hydrophilic serinol-substituted polymer 
was selected for LD50 studies. Mice were intravenously injected with polymer 
at a dose of 500 mg/kg. The animals were observed every 30 min for the first 
4 h and daily after, for a total of 14 days. All mice exhibited good health, with 






Fig. 6.4. Cell viability of HEK293 cells after treated with water-soluble 
polycarbonates and PEG (labeled as 5 kDa and 10 kDa) for 48 h. 
 
6.3.4. Micelle formation  
One strategy commonly explored for hydrophobic drug delivery is the use of 
diblock copolymers that self-assemble into micelles. PEG-based diblock 
copolymers are very common in the literature where water-soluble PEG 
stabilizes the micelles in water and serum. Diblock copolymers comprising 
water-soluble polycarbonates with a hydrophobic polycarbonate second block 
(poly(MTC-OEt)) were selected for this study. These polymers were 
synthesized by first polymerizing MTC-OC6F5 followed by the sequential 
addition of MTC-OEt (Scheme 6.2). Two different 
poly(MTC-OC6F5)-b-poly(MTC-OEt) polymers were made with varying 
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lengths of poly(MTC-OEt), which were subsequently subjected to the 
postmodification protocol using various amino alcohols. As shown in Table 
6.2, diblock copolymers with controlled structure and narrow molecular 
weight distributions were obtained. Representative 1H NMR spectra of the 
diblock copolymers can be found in appendix 4 (Fig. A4.7-A4.11). 




Scheme 6.2. Synthesis of diblock copolymers containing water-soluble 
polycarbonate block and the hydrophobic block poly(MTC-OEt). 
 






Light scattering was performed on these materials in water to determine 
micelle size (Table 6.3). Diblock copolymer wherein the hydrophilic block 
contained a single hydroxyl unit and propyl spacers between the amide and 
hydroxyl group (Table 6.3, entries B-2 and B-3) formed larger micelles than 
the diblock copolymers with more hydrophilic side groups. This result 
indicates that the materials in the former category are not hydrated enough to 
create small stable micelles suitable for drug delivery. The other, more 
hydrophilic diblock copolymers (entries B-1, B-4, and B-5) self-assembled 
into micelles on the order of 10−20 nm. Lastly, aggregation studies were 
performed on the serinol- and 3-aminopropanol-substituted diblock 
copolymers (Fig. 6.5). The serinol-substituted micelles were stable in serum 
for at least 8 h. The micelles formed from the diblock copolymer with a longer 
hydrophobic block (P-2 backbone) demonstrated higher stability, and particle 
size remained below 50 nm even after 48 h. The 3-aminopropanol-substituted 
polymers with lower hydrophobicity (entry B-2, P-3 backbone) were less 
stable with the micelle size being less consistent over time. Similar to the 
serinol-substituted polymers, the more hydrophobic 
3-aminopropanol-substituted polymers exhibited better stability. Changing the 
micelle media from water to 10% serum did cause a decrease in micelle size 
for the 3-aminopropanol-substituted polymers (series B-3). For backbone P-2, 
the micelle size decreased from 176 to 21 nm, and for backbone P-3 the 
micelle size decreased from 610 to 73 nm (Table 6.3 and Fig. 6.5). The 
145 
 
diblock stability studies indicate that select water-soluble polycarbonates can 
serve as the hydrophilic block of amphiphilic diblock copolymers for 
preparation of micellar drug delivery systems. 
 
























3-amino propanol, m=50, n=20




Fig. 6.5. Particle size measured by DLS as a function of time for diblock 
copolymers substituted with serinol and 3-aminopropanol dissolved in 10% 






In this chapter, hydrophilic polycarbonates containing hydroxyl groups 
attached to the polymer side chain via an amide linkage were prepared by the 
acid-catalyzed ring-opening-polymerization of the cyclic carbonate 
MTC-OC6F5 and subsequent reaction with amino alcohols. Quantitative, 
chemoselective substitution of the activated ester groups to the corresponding 
amides was observed, and polymer dispersity was maintained after 
functionalization. These materials were designed with OH side groups and 
amide linkages to promote hydrogen bonding with water molecules to 
facilitate polymer hydration. These materials exhibited nonfouling properties 
similar to PEG with the added benefit of being both enzymatically and 
hydrolytically degradable. Cytotoxicity assays and LD50 evaluations indicate 
that these polymers have toxicity similar to that of the PEG controls. Also, 
preliminary micelle studies indicated that these materials are promising 















The aim of this study is to develop biodegradable and functional polymeric 
micelles self-assembled from diblock copolymers of PEG and functionalized 
polycarbonate as drug carriers for the delivery of anticancer drugs for cancer 
treatments, especially to tackle the problems of CSCs and MDR. The 
co-delivery of two drugs using mixed micelles formed from 
acid-functionalized copolymer and urea-functionalized copolymer was 
employed to target cancer cells and CSCs simultaneously (chapter 3). Then, in 
order to enhance the tumor targeting effect and increase intracellular drug 
release, pH-sensitive polymeric micelles have been developed based on two 
different strategies (chapter 4 and 5). Finally, to optimize the micellular 
formulation, biodegradable hydrophilic polycarbonates have been designed 
and synthesized as alternatives to PEG, the most widely used micelle 
shell-forming material (chapter 6). The hypothesis is that these biodegradable 
polymeric micelles could serve as safe and effective drug carriers for the 
delivery of anticancer drugs to eradicate CSCs and MDR cancer cells, and the 
biodegradable hydrophilic polycarbonates would be alternative micellular 
shell-forming materials which could overcome the limitations of PEG in the 




Studies performed and results presented in this thesis have successfully proved 
the hypothesis. Firstly, in chapter 3, mixed micelles were prepared using 
diblock copolymers of PEG and carboxylic acid-functionalized polycarbonate 
as well as PEG and urea-functionalized polycarbonate for the co-delivery of 
anticancer drug doxorubicin (DOX) and thioridazine (THZ) that could 
specifically target CSCs to eradicate both cancer cells and CSCs, the efficacy 
of which was evaluated in two breast cancer cell lines BT-474 and MCF-7 
cells. As a result, the co-delivery of the two drugs using mixed micelles not 
only enhanced the anticancer efficiency but also significantly reduced the 
systemic toxicities of the free drugs in vivo. Both THZ and THZ-loaded mixed 
micelles effectively targeted CSCs in sorted side population (SP) cells or 
unsorted cancer cells. The combination therapy using the two drug-loaded 
mixed micelles could achieve synergistic anticancer effects both in vitro and in 
vivo, which made it a promising strategy to combat MDR in cancer treatment 
[250]. 
 
However, one major issue of the micellular drug delivery system is that drugs 
are often unable to be released timely and effectively in the tumor site or 
cancer cells. Exploiting the acidic environment in the endosomes, pH-sensitive 
micelles were designed to enhance intracellular drug release. In chapter 4, the 
pH-sensitive micelles were prepared by self-assembly of diblock copolymers 
of PEG and DOX-conjugated polycarbonate. DOX-conjugated polymers were 
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obtained by reacting DOX with aldehyde groups in the polycarbonate to form 
acid-cleavable Shiff-base bond. The results showed efficient DOX release 
from the micelles triggered by the endosomal pH. When evaluating the effects 
of DOX-conjugated micelles in circumventing MDR using MDR breast cancer 
cell line MCF-7/Adr cells, the micelles showed much higher cellular uptake in 
MCF-7/Adr cells, and demonstrated higher killing efficiency than free DOX 
[251].  
 
In addition, in chapter 5, another pH-sensitive micellular system was designed 
and prepared using diblock copolymer of PEG and boronic acid-functionalized 
polycarbonate for the delivery of DOX. In order to enhance the stability of 
micelles, the boronic acid-functionalized polycarbonate copolymer was mixed 
with the copolymer of PEG and urea-functionalized polycarbonate to form 
mixed micelles. To better mimic the real life tumor environment, the antitumor 
activities of these micelles were investigated on BT-474 cells using 3D 
tumorspheres model to see of the effects were consistent with those obtained 
on 2D monolayer cell model. The results showed showed accelerated drug 
release at pH 5.0, than that at pH 7.4 for both DOX/B and DOX/B+U micelles, 
due to protonation of boronic acid groups at lower pH and disruption of the 
ionic interactions with the drug payloads. Owing to the enhanced cellular 
uptakes, both micelles killed the 2D monolayer BT-474 cells more effectively 
than free DOX. Moreover, in 3D tumorspheres, both micelles showed higher 
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cellular uptakes and stronger penetration abilities than free DOX. Thus, 
boronic acid based pH-sensitive drug delivery systems could be promising 
candidates for effective anticancer therapy and easy clinical translation in the 
future. 
 
Finally, we came to investigate a structural problem in micelle formulation. 
Usually, PEG is the gold standard shell-forming block to provide stealth 
property o micelles. However, PEG is not biodegradable, and thus has several 
limitations, which warrant the development of alternative shell-forming 
polymers. In chapter 6, to optimize the formulation of polymeric micelles, 
biodegradable hydrophilic polycarbonates were designed and synthesized for 
the replacement of PEG. These polymers showed stealth and antifouling 
properties without causing toxicity to mice. Also, diblock copolymers 
synthesized based on these hydrophilic polycarbonates could form nanosize 
micelles with stealth property in aqueous solution [252]. These copolymers 
could be further explored for their potential to deliver anticancer drugs to 
combat problems such as MDR. 
 
All in all, the results shown in this thesis have strongly supported the initial 
hypothesis that polymeric micelles prepared using diblock copolymers of PEG 
and biodegradable functional polycarbonates are safe and effective drug 
carriers for the delivery of anticancer drugs for cancer treatment, especially to 
151 
 
tackle the problems of MDR and to target and eradicate CSCs. Furthermore, 
we have also developed a new class of biodegradable hydrophilic 
polycarbonate polymers as alternatives of PEG. These micellular 
nanoparticulate systems hold great potential for the delivery of anticancer 
drugs to target both cancer cells and CSCs in order to circumvent MDR, and 
to achieve targeted and enhanced drug delivery to the acidic tumor 
micro-envionment. Also, the hydrophilic polycarbonates as PEG alternatives 
are promising candidates as novel micellular drug delivery systems to be more 
thoroughly investigated in the future. 
 
7.2. Future directions 
 
Although the findings in this thesis have effectively supported the hypothesis 
that proposed initially, further investigations can be performed to evaluate the 
antitumor efficacies of these micellular systems and the effectiveness of using 
the hydrophilic polycarbonates as micelle shell-forming materials. 
 
Firstly, in chapter 3, the results have demonstrated that the co-delivery of 
DOX and THZ using mixed micelles could effectively inhibit the tumor 
growth and decrease the population of CSCs in vivo studies on nude mice 
bearing BT-474 xenograft over an observation period of 16 days after the first 
treatment. In the future, metastastic tumor models by injecting sorted CSCs or 
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other metastatic cancer cell lines (e.g. 4T1 and MDA-MBA-231) into mice 
can be used to further investigate the effectiveness of the combination therapy 
in inhibiting the cancer metastasis. In addition, the observation time after the 
treatment can be prolonged to evaluate the effectiveness of the combination 
therapy on prohibiting the tumor recurrence. 
 
Secondly, although the pH-sensitive DOX-conjugated micelles containing 
Schiff-base bond showed promising anti-MDR effects in vitro, their effects in 
overcoming MDR in vivo have not been evaluated. The in vivo mice tumor 
model can be established using MDR cancer cell line MCF-7/Adr, and then 
the antitumor effect of DOX-conjugated micelles can be further investigated in 
this tumor model.  
 
Thirdly, the pH-sensitive DOX-loaded micelles prepared using boronic 
acid-functionalized copolymer and urea-functionalized copolymer showed 
enhanced antitumor activity and greater penetration ability in 3D tumorspheres 
than free DOX in vitro. The tumor targeting effect of these micelles can be 
further evaluated by live imaging following injection of Dir-loaded micelles 
into mice bearing BT-474 tumors. Furthermore, the systemic toxicities and 
antitumor activities of these micelles can be investigated in BT-474 tumor 




Last but not least, our studies have demonstrated that the hydrophilic 
polycarbonate polymers showed antifouling property without causing toxicity 
to mice. The preliminary studies also showed that these polymers could be 
used as micelle shell-forming materials to provide stealth properties. However, 
more comprehensive studies are needed in the future to optimize the 
micellular formulations to achieve small particle size, narrow size distribution 
and high systemic stability. In addition, micelles prepared based on these 
hydrophilic polycarbonates can be used for the delivery of various anticancer 
drugs, and their efficacy can be further evaluated both in vitro and in vivo and 
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Appendix 1: Synthesis and characterization of urea-functionalized 
(PEG-PUC) and acid-functionalized (PEG-PAC) diblock copolymers 
 
The urea-functionalized (PEG-PUC) and acid-functionalized (PEG-PAC) 
diblock copolymers were synthesized in our lab by Dr. Victor Ng in IBN. The 
details for organocatalytic ROP of the respective monomers with PEG are 
provided below. All polymerizations were carried out in a glove-box under 
nitrogen atmosphere. 
 
Synthesis of urea-functionalized (PEG-PUC) and benzyl-protected 
acid-functionalized (PEG-P(MTC-OBn)) block copolymers 
 
PEG-PUC: To a mixture of MTC-urea (242 mg, 0.75 mmol), PEG (500 mg, 
0.05 mmol, Mn 10,000 g/mol, PDI 1.04) and thiourea catalyst (TU) (18.5 mg, 
0.05 mmol) dissolved in dichloromethane (5 mL) was added sparteine (11.5 
µL, 0.05 mmol) to initiate the ROP. The homogeneous solution was stirred for 
18 h at ambient temperature. Benzoic acid (25 mg; ~ 4 eqv.) was added to 
quench the polymerization, dropwise and the crude polymer precipitated in 50 
mL diethyl ether. The white precipitate was collected after centrifugation, 
dried briefly and re-dissolved in dichloromethane. The crude polymer was 
re-precipitated four times to ensure complete removal of impurities and dried 
under vacuo to give a white solid (85%). PDI 1.12. 1H NMR (400 MHz, 
DMSO-d6, 22 °C):  8.53 (s, br, 13H, PhNH-), 7.36 (m, 26H, PhH), 7.18 (m, 
26H, PhH), 6.86 (m, 13H, PhH), 6.20 (s, br, 13H, -CH2NH-), 4.05 – 4.25 
(overlapping peaks, 78H, MTC-CH2- and -COOCH2-), 3.50 (s, 906H, H of 
MPEG), 3.33 (s, 26H, -CH2NHCO-), 1.13 (s, 39H, -CH3). 
 
PEG-P(MTC-OBn): In a similar manner, DBU (7.5 µL, 0.05 mmol) was 
added to a mixture of MTC-OBn (188 mg, 0.75 mmol) and PEG (500 mg, 
0.05 mmol, Mn 10,000 g/mol, PDI 1.04) dissolved in dichloromethane (5 mL) 
to start the ROP. The mixture was stirred for 3 h at ambient temperature and 
subsequently quenched by the addition of benzoic acid (25 mg; ~ 4 eqv.). 
Identical purification protocol was employed as for PEG-PUC polymer. Yield, 
80%; PDI 1.10. 1H NMR (400 MHz, CDCl3, 22 °C):  7.31 (m, 60H, PhH), 
5.13 (m, 24H, PhCH2-), 4.27 (m, 48H, MTC-CH2-), 3.64 (s, 906H, H of PEG), 
1.21 (m, 36H, -CH3).  
 
Deprotection of benzyl groups in PEG-P(MTC-OBn): A mixture of 
PEG-P(MTC-OBn) (0.5 g) and Pd-C (10% w/w, 0.2 g) in THF/methanol (7.5 
mL each) was stirred under hydrogen (7 atm) overnight. The reaction mixture 
was then filtered through Celite wetted with THF after removal of hydrogen. 
Additional THF and methanol washings were performed to ensure complete 
transfer of the deprotected polymer. The filtrate was collected, and the 
solvents were evaporated. The resultant residue was re-dissolved in THF and 
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precipitated with diethyl ether before being freeze-dried under vacuo. The 
PEG-acid diblock copolymer PEG-PAC (or PEG-P(MTC-OH)) was obtained 
as a powdery white solid (yield: >90 %). 
 
Characterizations: 1H NMR spectra were obtained on a Bruker Avance 400 
instrument at 400 MHz. Gel permeation chromatography (GPC) was 
performed in tetrahydrofuran (THF) using a Waters system equipped with four 
5 μm Waters columns (300 mm × 7.7 mm) connected in series with an 
increasing pore size (100, 1000, 105, and 106 Å), a Waters 410 differential 
refractometer, and a 996 photodiode array detector. The system was calibrated 




































Appendix 2: Synthesis and characterization of aldehyde-functionalized 
monomer and diblock copolymers 
 
The aldehyde-functionalized monomer and diblock copolymers were 
synthesized by our collaborator Dr. Daniel J. Coady in IBM Almaden 
Research Center. The details for organocatalytic ROP of the respective 
monomers with PEG are provided below. All polymerizations were carried out 
in a glove-box under nitrogen atmosphere. 
 
4-(3-Hydroxy-propoxy)-benzaldehyde: To a solution of 
4-hydroxybenzaldehyde (2.0 g, 16.4 mmol) and K2CO3 (3.9 g, 27.8 mmol) in 
DMF (20 mL) was added 3-bromopropanol (1.8 mL, 19.7 mmol). The mixture 
was stirred at room temperature for 16 h, diluted with H2O (60 mL), and 
extracted with EtOAc (3x20 mL). The combined organic layers were washed 
with 1 N NaOH (2x), H2O (1x), and brine (1x). The organic layer was dried 
(Na2SO4) and concentrated to afford 3.2 g (89 %) of a yellow oil. 
 
MTC-Bz: A flask was charged with 4-(3-hydroxy-propoxy)-benzaldehyde (2 g, 
11.1 mmol), CGC-1 (4.7 g, 14.4 mmol), proton sponge (1.2 g, 5.5 mmol), THF 
(25 mL) and stir bar. The reaction mixture was then stirred for 18 h followed 
by the addition of ammonium acetate (2 g, 25.9 mmol). The reaction mixture 
was then reduced to ~ 15 mL and purified directly by flash chromatography. 
 
PC-1: In a nitrogen filled glove box a vial was charged with monomethyl PEG 
5k (0.256 g, 0.05 mmol), MTC-Bz (0.25 g, 0.77 mmol), thiourea (0.01 g, 
0.027 mmol), DCM (1 g) and stir bar. The polymerization was then initiated 
by the addition of DBU (4 L, 0.026 mmol). After greater than 90% 
conversion the reaction was quenched with acetyl chloride and precipitated 
into ether, yielding 0.474 g (94 %) white polymer (Mn – 9.9 kDa, PDI – 1.04).   
 
PC-2: In a nitrogen filled glove box a vial was charged with monomethyl PEG 
8k (0.41 g, 0.05 mmol), MTC-Bz (0.25 g, 0.77 mmol), thiourea (0.01 g, 0.027 
mmol), DCM (1 g) and stir bar. The polymerization was then initiated by the 
addition of DBU (4 L, 0.026 mmol).  After greater than 90% conversion the 
reaction was quenched with acetyl chloride and precipitated into ether, 
yielding 0.634 g (96%) white polymer (Mn – 14.6 kDa, PDI – 1.04).   
 
Characterizations: 1H NMR spectra of monomers and polymers were 
recorded on a Bruker Advance 400 NMR spectrometer at 400 MHz at room 
temperature. Fourier transform infrared (FT-IR) spectra were obtained by 
directly loading samples into a FT-IR spectrometer (Perkin Elmer Spectrum 
100) for IR analysis. The scanning wave number ranged from 4000 to 600 
cm–1. GPC analysis was conducted with a Waters HPLC system consisting of a 
2690D separation module with Styragel HR1 (DMF) column (size: 300 × 7.8 
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mm) and a Waters 410 differential refractometer detector. DMF was used as 
the mobile phase and the flow rate was 1 mL/min. Number-average molecular 
weights and polydispersity indices of the conjugates were calculated from a 

























Appendix 3: Synthesis and characterization of boronic 
acid-functionalized monomer and diblock copolymer 
 
The boronic acid-functionalized monomer and diblock copolymer were 
synthesized by David Voo in IBN. The details for organocatalytic ROP of the 
respective monomers with PEG are provided below. All polymerizations were 
carried out in a glove-box under nitrogen atmosphere. 
 
Synthesis of MTC-PPB monomer: Briefly, in a dry two-neck 500 mL round 
bottom flask equipped with a stir bar, MTC-OH (3.08 g, 19.3 mmol) was first 
dissolved in dry THF (50 mL) with 5-8 drops of dimethylformamide (DMF). 
Subsequently, oxalyl chloride (3.3 mL) was added in one shot (pure form), 
followed by an additional 20 mL of THF. The solution was stirred for 90 min, 
after which volatiles were blown dried under a strong flow of nitrogen to yield 
a pale yellow solid intermediate (5-chlorocarboxy-5-methyl-1,3-dioxan-2-one, 
MTC-Cl). The solid was then subjected to heat at 60 °C for 2-3 min for the 
removal of residual solvent, and was re-dissolved in dry dichloromethane 
(CH2Cl2, 50 mL), followed by immersing the flask in an ice bath at 0 °C. A 
mixture of 4 hydroxymethyl phenylboronic acid pinacol ester (4.19 g, 17.88 
mmol) and triethylamine (1.77 mL, 19.3 mmol) were dissolved in dry CH2Cl2 
(50 mL), which was added dropwise to the flask over a duration of 30 min, 
and allowed to stir at room temperature (~ 22 ºC) for an additional 2.5 h 
immediately after complete addition. The reacted mixture was quenched by 
addition of 50 mL of brine, and the organic solvent was collected after 
separation. After removal of solvent, the crude product was purified by 
silica-gel flash column chromatography via a hexane-ethyl acetate solvent 
system (gradient elution up to 20 % vol. ethyl acetate) followed by a solvent 
switch to dichloromethane-ethyl acetate (gradient elution up to 20% vol. ethyl 
acetate) to yield MTC-PPB as a white solid. The crude product was further 
purified by recrystallization. The solid was dissolved in 50 mL of diethyl ether 
and the residues were filtered. The filtrate was dried and subsequently 
dissolved in 2 ml of diethyl ether and ethyl acetate (1 ml each), followed by 
addition of 50 mL of hexane. The crystals are allowed to form at room 
temperature for 1 day, and are subsequently obtained by washing the crystals 
with cold hexane.  1H NMR (400 MHz, CDCl3, 22 ºC): δ 7.83-7.32 (m, 4H, 
-C6H4B=), 5.22 (s, 2H, - CH2C6H4-), 4.72-4.18 (m, 4H, -COOCH2-), 1.34 (s, 
12H, -OC(CH3)4CO-), 1.32 (m, 3H, -CH3). 
 
Synthesis of boronic acid functionalized diblock copolymer (PEG-PBC): 
Details of the metal-free organocatalytic ring-opening polymerization for the 
diblock copolymer (A-B) are given as an example. In a glove-box, 0.222 g 
(0.022 mmol) of 10 kDa mPEG-OH initiator and 0.376 g (1 mmol) of 
MTC-PPB were charged in a 20 mL glass vial equipped with a stir bar. 
Dichloromethane was added and the monomer concentration was adjusted to 2 
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M. Once the initiator and monomer were completely dissolved, 8.3 µL (0.06 
mmol) of DBU was added to initiate the polymerization. After 3.5 h of stirring 
at room temperature, the reaction was quenched with 30 mg of benzoic acid. 
Subsequently, the polymer intermediate was purified via precipitation twice in 
cold diethyl ether, and was dried on a vacuum line until a constant weight was 
achieved. 1H NMR (400 MHz, CDCl3, 22 ºC): δ 7.83-7.27 (m, 48H, -C6H4B=), 
5.23-5.02 (m, 24H, - CH2C6H4-), 4.49-4.13 (m, 48H, -COOCH2-), 3.84.-3.43 
(m, 908H, -OCH2CH2- from 10kDa PEG), 3.38 (s, 3H, CH3-PEG-), 1.39-1.27 
(m, 144H, -OC(CH3)4CO-), 1.26-1.16 (m, 36H, -CH3). 
 
The protected polymer was then deprotected by dissolving in 14 mL of 
methanol and THF (1:1) and 10 equivalents (with respect to mols of protected 
phenylboronic pinacol pendant groups) of benzene-1,4-diboronic acid and 
DOWEX® 50W-X2 acidic resins were added to a 50 ml rbf containing the 
protected polymer. The rbf was subsequently heated to 50 °C with overnight 
stirring. After which, the solvents were removed under vacuum and the 
deprotected polymer was dissolved in 10 mL of isopropanol and acetonitrile 
(1:1) and placed within a dialysis bag of 1000 MW cut-off. Dialysis was 
carried for the next 2 days at room temperature using 1:1 isopropanol and 
acetonitrile. Finally, the solvents were removed and the polymer was 
lyophilized to obtain an off-white polymer. 1H NMR (400 MHz, DMSOd, 22 
ºC): δ 8.22-7.88 (m, 24H, -B(OH)2), 7.84-7.15 (m, 48H, -C6H4B=), 5.23-4.96 
(m, 24H, - CH2C6H4-), 4.46-4.02 (m, 48H, -COOCH2-), 3.71.-3.14 (m, 909H, 
-OCH2CH2- from 10 kDa PEG), 3.23 (s, 3H, CH3-PEG-), 1.25-1.05 (m, 36H, 
-CH3). 
 
Characterizations: 1H NMR spectra were obtained on a Bruker Avance 400 
instrument at 400 MHz. Gel permeation chromatography (GPC) was 
performed in tetrahydrofuran (THF) using a Waters system equipped with four 
5 μm Waters columns (300 mm × 7.7 mm) connected in series with an 
increasing pore size (100, 1000, 105, and 106 Å), a Waters 410 differential 
refractometer, and a 996 photodiode array detector. The system was calibrated 














Appendix 4: Synthesis and characterization of biodegradable hydrophilic 
polycarbonate polymers 
 
The biodegradable hydrophilic polycarbonate polymers were synthesized by 
our collaborator Dr. Amanda C. Engler in IBM Almaden Research Center. The 
details for organocatalytic ROP of the respective monomers are provided 
below. All polymerizations were carried out in a glove-box under nitrogen 
atmosphere. 
 
Synthesis of poly(MTC-OC6F5): In a nitrogen-charged glovebox, benzyl 
alcohol (0.050 g, 0.46 mmol) and MTC-OC6F5 monomer (3.02 g, 9.25 mmol) 
were dissolved in dichloromethane (12 mL). The catalyst, triflic acid (0.069 g, 
0.46 mmol), was added, and the reaction mixture was stirred at room 
temperature overnight. The crude polymer solution was precipitated into 
hexanes to yield a white solid (3.0 g, 97%). From GPC using THF as eluent, 
Mn = 6200 Da, PDI = 1.15, DP = 20 (m = 20 in the above reaction). 1H NMR 
(400 MHz, CDCl3): δ 4.48 (s, 4H, CH2), 1.51 (3H, CH3). 
 
Representative synthesis of poly(MTC-OC6F5)-b-Poly(MTCOEt): In a 
nitrogen-charged glovebox, 3-butyn-1-ol initiator (0.085 g, 0.12 mmol) and 
MTC-OC6F5 monomer (1.98 g, 6.06 mmol) were dissolved in 
dichloromethane (8 mL). The catalyst, triflic acid (0.045 g, 0.30 mmol), was 
added, and the reaction mixture was stirred at room temperature overnight. 
The reaction progress was monitored by 1H NMR, which showed 
near-complete conversion (93%) after 18 h. At this point, MTC-OEt monomer 
(0.57 g, 3.03 mmol) was added, and the reaction was allowed to stir at room 
temperature before being stopped at 73% conversion. The crude polymer was 
precipitated into hexanes to afford a white solid (2.36 g, 91.8%). 1H NMR 
(400 MHz, CDCl3): δ 4.48 (s, CH2 poly(MTC-OC6F5), 4H), 4.26 (m, CH2 
poly(MTC-OEt), 4H), 4.20 (m, CH2CH3 poly(MTC-OEt), 2H), 1.51 (s, CH3, 
3H) poly(MTC-OC6F5), 1.26 (m, CH3 poly(MTC-OEt), 3H), 1.26 (m, 
CH2CH3 poly(MTC-OEt), 3H). 
 
Representative postpolymerization functionalization: Poly-(MTC-OC6F5) 
(200 mg, 0.613 mmol repeat units) was dissolved in 1 mL of acetonitrile 
(MeCN). 2-Aminoethanol (0.039 g, 0.64 mmol) and triethylamine (0.065 g, 
0.644 mmol) were dissolved in 1 mL of MeCN and added dropwise to the 
polymer solution, whereupon a white precipitate began to form. An additional 
1 mL of DMF was added to produce a clear solution. The reaction was 
allowed to proceed for an additional 2 h, and then it was precipitated into ether. 
A white solid was recovered, dialyzed against water (pH 4, molecular weight 
cutoff of 1000 Da), freeze-dried, and analyzed by GPC (DMF) and 1H NMR. 
Please note that the dialysis is performed at pH 4 after precipitation into ether. 
We found that if the dialysis was performed under basic aqueous conditions 
183 
 
(pH > 7.5) after 12 h, polymer degradation was observed (i.e., no polymer was 
left in the 1000 Da cut-off dialysis bag). 
 
Characterizations: 1H NMR spectra were obtained on a Bruker Avance 400 
instrument at 400 MHz. Gel permeation chromatography (GPC) was 
performed in tetrahydrofuran (THF) using a Waters system equipped with four 
5 μm Waters columns (300 mm × 7.7 mm) connected in series with an 
increasing pore size (100, 1000, 105, and 106 Å), a Waters 410 differential 
refractometer, and a 996 photodiode array detector. The system was calibrated 
with polystyrene standards. GPC analysis was also performed in 
N,N-dimethylformamide (DMF) spiked with 0.01 M LiBr using a Waters 
system equipped with two Agilent PolyPore columns (300 mm × 7.5 mm) 
connected in series and a Waters 410 differential refractometer. The system 
was calibrated with poly(methyl methacrylate) standards. 
 





Fig. A4.1. 1H NMR spectrum of polymer A-3 showing integration consistent 





Fig. A4.2. 1H NMR spectrum of polymer A-1. 
 
 




Fig. A4.4. 1H NMR spectrum of polymer A-4. 
 
 




Fig. A4.6. 1H NMR spectrum of polymer A-6. 
 
Representative 1H NMR (400 MHz, d6 DMSO) spectra of each diblock 
copolymer are below. The Poly(MTC-OEt) peaks are visible at 4.1 ppm and 
1.1 ppm. All other peaks match what would be expected for quantitative 
substitution. In some 1H NMR, DMF impurity is present. 
 
 
Fig. A4.7. 1H NMR spectrum Poly(MTC-OC6F5)50-b-Poly(MTC-OEt)20 




Fig. A4.8. 1H NMR spectrum Poly(MTC-OC6F5)50-b-Poly(MTC-OEt)20 
substituted with 3-aminopropanol. 
 
 
Fig. A4.9. 1H NMR spectrum Poly(MTC-OC6F5)50-b-Poly(MTC-OEt)20 




Fig. A4.10. 1H NMR spectrum Poly(MTC-OC6F5)50-b-Poly(MTC-OEt)20 




Fig. A4.11. 1H NMR spectrum Poly(MTC-OC6F5)50-b-Poly(MTC-OEt)20 
substituted with (±)-3-amino-1,2-propanediol (racemic). 
 
